Neuropsychiatric Systemic Lupus Erythematosus

Autoimmune MONDO:0007915 Pathograph 15 Systemic Lupus Erythematosus Autoimmune Disease Neurological Disease

Neuropsychiatric systemic lupus erythematosus is the nervous-system manifestation spectrum of systemic lupus erythematosus. It includes central and peripheral nervous-system syndromes such as seizure, psychosis, cognitive dysfunction, cerebrovascular disease, acute confusional state, chorea, demyelinating syndromes, and peripheral neuropathy. Attribution is difficult: presentations may reflect lupus-driven inflammation, antiphospholipid-related thrombosis, both mechanisms, or non-SLE mimics such as infection, metabolic disease, medication effects, or primary psychiatric and neurologic disorders. No standalone MONDO or Orphanet disease term was found in the local ontology resources, so this entry is anchored to the parent systemic lupus erythematosus term while preserving the NPSLE preferred term.

Ask OpenScientist

Ask a research question about Neuropsychiatric Systemic Lupus Erythematosus. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Definitions
4
Pathophys.
11
Phenotypes
15
Pathograph
4
Genes
6
Treatments
2
Subtypes
70
References
2
Deep Research
📘

Definitions

2
ACR 1999 neuropsychiatric lupus syndrome framework
The American College of Rheumatology nomenclature provides standardized case definitions and ascertainment guidance for 19 neuropsychiatric syndromes seen in SLE, spanning central and peripheral nervous-system involvement.
CASE_DEFINITION Patients with SLE and neurologic or psychiatric manifestations.
Neuropsychiatric syndrome spectrum
The case-definition framework requires syndrome-specific clinical assessment, important exclusions, and appropriate ascertainment methods rather than a single pathognomonic laboratory test.
Core clinical characteristics
  • Seizure
  • Psychosis
  • Anxiety
  • Cognitive impairment
  • Delirium Acute confusional state in the ACR/EULAR NPSLE literature.
  • Peripheral neuropathy
  • CNS demyelination Maps the ACR demyelinating-syndrome category.
Show evidence (1 reference)
PMID:10211873 SUPPORT Other
"Case definitions including diagnostic criteria, important exclusions, and methods of ascertainment were developed for 19 NPSLE syndromes."
This supports the syndrome-spectrum criteria set used to organize the ACR neuropsychiatric lupus framework.
Show evidence (2 references)
PMID:10211873 SUPPORT Other
"Case definitions including diagnostic criteria, important exclusions, and methods of ascertainment were developed for 19 NPSLE syndromes."
This is the landmark ACR nomenclature and case-definition framework for NPSLE syndrome attribution and reporting.
PMID:10211873 SUPPORT Other
"The American College of Rheumatology (ACR) Nomenclature for NPSLE provides case definitions for 19 neuropsychiatric syndromes seen in SLE, with reporting standards and recommendations for laboratory and imaging tests."
The conclusion supports the 19-syndrome framework and its use in clinical research and specialist-supported diagnosis.
Attribution and exclusion-based diagnosis
Suspected NPSLE is first evaluated like the same neurologic or psychiatric syndrome in a patient without SLE. Attribution to lupus follows exclusion of non-SLE causes and assessment for inflammatory, autoimmune, thrombotic, or mixed mechanisms.
DIAGNOSTIC_CRITERIA Diagnostic workup of new neurologic or psychiatric events in patients with SLE.
EULAR diagnostic workup
Workup includes targeted studies such as CSF analysis, EEG, neuropsychological testing, nerve-conduction studies, and MRI according to the presenting syndrome.
Minimum required: 1
Show evidence (1 reference)
PMID:20724309 SUPPORT Other
"The diagnostic work-up of suspected NPSLE is comparable to that in patients without SLE who present with the same manifestations, and aims to exclude causes unrelated to SLE."
EULAR explicitly frames diagnosis as syndrome-based evaluation and exclusion of non-SLE causes.
Show evidence (1 reference)
PMID:26809245 SUPPORT Other
"Due to the lack of a gold standard, the attribution of NP symptoms to SLE represents a clinical challenge that obligates the strict exclusion of any other potential cause."
The management review supports the attribution-and-exclusion diagnostic framing used here.
◆

Subtypes

2
Inflammatory or autoimmune NPSLE
NPSLE manifestations attributed primarily to lupus-driven inflammation or autoimmunity, including optic neuritis, transverse myelitis, peripheral neuropathy, refractory seizures, psychosis, and acute confusional state, especially when generalized lupus activity is present.
Show evidence (2 references)
PMID:20724309 SUPPORT Other
"Glucocorticoids and immunosuppressive therapy are indicated when NPSLE is thought to reflect an inflammatory process (optic neuritis, transverse myelitis, peripheral neuropathy, refractory seizures, psychosis, ACS) and in the presence of generalised lupus activity."
EULAR distinguishes inflammatory-process NPSLE manifestations that warrant glucocorticoids and immunosuppression.
PMID:26809245 SUPPORT Other
"High-dose glucocorticoids and intravenous cyclophosphamide remain the cornerstone for patients with severe symptoms that are thought to reflect inflammation or an underlying autoimmune process."
This treatment distinction supports an inflammatory/autoimmune subtype concept used in clinical decision-making.
Antiphospholipid-associated thrombotic NPSLE
Focal or vascular neuropsychiatric lupus manifestations driven by antiphospholipid-antibody-associated thrombosis or ischemia, especially cerebrovascular disease, seizures, and chorea.
Show evidence (2 references)
PMID:20724309 SUPPORT Other
"Strong risk factors (at least fivefold increased risk) are previous or concurrent severe NPSLE (for cognitive dysfunction, seizures) and antiphospholipid antibodies (for CVD, seizures, chorea)."
EULAR identifies antiphospholipid antibodies as strong risk factors for vascular and selected neurologic NPSLE manifestations.
PMID:18537650 SUPPORT Other
"Focal CNS manifestations, particularly TIA and stroke, are associated with the presence of antiphospholipid antibodies (aPL)."
This review supports a focal thrombotic/aPL-associated clinical subtype.
⚙

Pathophysiology

4
Autoimmune Neuroinflammation
Systemic lupus autoimmunity can extend to the nervous system through autoantibody production, immune-complex and complement activation, type I interferon signaling, cytokine-mediated inflammation, and intrathecal immune activation, producing diffuse or focal neuropsychiatric syndromes.
B cell link T cell link microglial cell link
immunoglobulin production link ↑ INCREASED neuroinflammatory response link ↑ INCREASED complement activation link ↑ INCREASED type I interferon-mediated signaling pathway link ↑ INCREASED
brain link choroid plexus link
Downstream
Blood-Brain Barrier Disruption Inflammatory mediators and complement can impair barrier integrity, allowing neuropathic antibodies and soluble mediators to reach brain parenchyma.
Show evidence (4 references)
PMID:26809245 SUPPORT Other
"In clinical practice, therapies are directed to a presumptive pathophysiologic process (inflammatory, thrombotic, or both)."
The review supports inflammatory and thrombotic mechanism clusters as the practical mechanistic framing for NPSLE.
PMID:41989680 SUPPORT Other
"aberrant activation of innate immunity by self-nucleic acids and consequent overproduction of Type I interferons (IFN-I) constitute a central pathogenic axis in NPSLE."
This review supports type I interferon-driven innate immune activation as a central inflammatory axis in NPSLE.
PMID:37369340 SUPPORT Model Organism
"interferon-stimulated genes (ISGs) were among the most highly upregulated genes in both regions and that gene pathways involved in cellular interaction and neuronal development were generally repressed among astrocytes, oligodendrocytes, and neurons."
The mouse spatial transcriptomics study supports CNS interferon signaling as a mechanistic contributor to neuropsychiatric lupus phenotypes.
+ 1 more reference
Blood-Brain Barrier Disruption
Disruption of the blood-brain barrier permits circulating neuropathic autoantibodies, complement components, cytokines, and chemokines to enter CNS tissue and interact with neurons, glia, and endothelial cells.
endothelial cell link astrocyte link
maintenance of blood-brain barrier link ↓ DECREASED astrocyte activation link ↑ INCREASED
blood brain barrier link
Downstream
Anti-NMDA-NR2A/B Neuronal Excitotoxicity Barrier disruption can allow anti-NR2/glutamate-receptor antibodies to access neuronal targets and alter synaptic signaling or neuronal survival.
Show evidence (3 references)
PMID:26809245 SUPPORT Other
"The BBB is a network of endothelial cells and pericyte and astrocyte projections that regulates the entry of soluble molecules and cells into the brain parenchyma."
The review defines the anatomical and cellular barrier interface relevant to NPSLE.
PMID:26809245 SUPPORT Other
"It has been proposed that a disruption of the integrity of the BBB may have a potential pathogenic role in NPSLE since this may permit the influx of neuropathic antibodies across the BBB."
This directly supports BBB disruption as a pathogenic step in NPSLE.
PMID:29846157 SUPPORT Human Clinical
"CONCLUSIONS: The data demonstrate that serum anti-Sm antibodies play a most important role in the disruption of BBB in NPSLE."
The patient serum/CSF study links anti-Sm autoantibodies to BBB dysfunction as measured by Q albumin.
Anti-NMDA-NR2A/B Neuronal Excitotoxicity
A subset of SLE patients have anti-NMDA-NR2A/B glutamate-receptor antibodies. When these antibodies reach CNS targets, they can alter NMDA receptor signaling, injure neurons, and contribute to cognitive, behavioral, mood, seizure, or psychiatric manifestations.
neuron link
glutamate receptor signaling pathway link ⚠ ABNORMAL chemical synaptic transmission link ⚠ ABNORMAL positive regulation of calcium ion transport link ↑ INCREASED
brain link
Show evidence (2 references)
PMID:25081016 SUPPORT Other
"Some of the anti-NMDA-NR2A/B antibodies associate with neuropsychiatric/cognitive/behavior/mood impairments in SLE patients, while others do not."
The review supports anti-NMDA-NR2A/B antibodies as a heterogeneous but relevant autoantibody class in NPSLE.
PMID:25081016 SUPPORT Other
"The anti-NMDA-NR2A/B antibodies can undoubtedly be very pathogenic, since they can kill neurons by activating NMDA receptors and inducing 'Excitotoxicity', damage the brain"
This supports neuronal excitotoxicity as a downstream mechanism for a subset of anti-NR2 antibody-positive disease.
Antiphospholipid-Associated Neurovascular Thrombosis
Antiphospholipid antibodies promote neurovascular risk through endothelial, platelet, coagulation, and complement-related prothrombotic mechanisms, producing ischemic or focal NPSLE manifestations such as cerebrovascular disease, seizures, and chorea.
endothelial cell link platelet link
blood coagulation link ↑ INCREASED platelet activation link ↑ INCREASED complement activation link ↑ INCREASED
Downstream
Ischemic Stroke Prothrombotic aPL-associated vascular injury can culminate in thrombotic cerebrovascular disease.
Show evidence (2 references)
PMID:20724309 SUPPORT Other
"Strong risk factors (at least fivefold increased risk) are previous or concurrent severe NPSLE (for cognitive dysfunction, seizures) and antiphospholipid antibodies (for CVD, seizures, chorea)."
This supports aPL-associated vascular and neurologic manifestations as a distinct mechanistic cluster.
PMID:18240179 SUPPORT Human Clinical
"Our data suggest an association between LAC and cerebrovascular disease at the time of SLE diagnosis and chorea over the disease course, but not between aPL and other neuropsychiatric manifestations."
The pediatric cohort supports lupus anticoagulant association with cerebrovascular disease and chorea.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Referential integrity issues (1):
  • Target 'Ischemic Stroke' (from 'Antiphospholipid-Associated Neurovascular Thrombosis') not found in named elements
Pathograph: causal mechanism network for Neuropsychiatric Systemic Lupus Erythematosus Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Cardiovascular 1
Cerebrovascular Disease OCCASIONAL Ischemic stroke (HP:0002140)
Show evidence (2 references)
PMID:20724309 SUPPORT Other
"Common (cumulative incidence > 5%) manifestations include cerebrovascular disease (CVD) and seizures"
EULAR classifies cerebrovascular disease as a common cumulative NPSLE manifestation.
PMID:34468807 SUPPORT Human Clinical
"Central nervous system involvement defined as neuropsychiatric lupus presents wide clinical findings varying from stroke and seizures to psychosis and cognitive dysfunction."
This case report review statement supports stroke as part of the NPSLE phenotype spectrum.
Nervous System 10
Seizure OCCASIONAL Seizure (HP:0001250)
Show evidence (3 references)
PMID:20724309 SUPPORT Other
"Common (cumulative incidence > 5%) manifestations include cerebrovascular disease (CVD) and seizures"
EULAR classifies seizures as a common cumulative NPSLE manifestation.
PMID:33626435 SUPPORT Other
"The prevalence of explicit episodes of seizures among SLE patients, varies from 2 to 8%."
The scoping review provides an SLE-level seizure prevalence range.
ORPHA:536 SUPPORT Other
"HP:0001250 | Seizure | Occasional (29-5%)"
Orphanet classifies seizure as an occasional phenotype in systemic lupus erythematosus.
Psychosis VERY_RARE Psychosis (HP:0000709)
Show evidence (2 references)
PMID:30375754 SUPPORT Human Clinical
"Among 28 of 1,826 patients with psychosis (1.53%), 26 of 28 (93%) had a single psychotic event, while 1 patient had 2 discrete events and 1 patient had 3 discrete events."
The large international inception cohort supports psychosis as a rare NPSLE event.
PMID:30375754 SUPPORT Human Clinical
"Using a well‐defined process for determining attribution, we confirmed that the majority of psychotic events were due to SLE."
The cohort supports lupus attribution for most psychotic events under the broader attribution model.
Cognitive Impairment Cognitive impairment (HP:0100543)
Show evidence (2 references)
PMID:10211873 SUPPORT Other
"A short neuropsychological test battery for the diagnosis of cognitive deficits was proposed."
The ACR case-definition paper supports formal neuropsychological evaluation of NPSLE cognitive dysfunction.
PMID:38332909 SUPPORT Human Clinical
"Of 290 patients, 40% (n=116) had CI."
This large SLE cohort quantifies cognitive impairment and supports its clinical relevance, though it is not itself an NPSLE-attribution study.
Depression OCCASIONAL Depression (HP:0000716)
Show evidence (2 references)
PMID:20724309 SUPPORT Other
"relatively uncommon (1-5%) are severe cognitive dysfunction, major depression, acute confusional state (ACS), peripheral nervous disorders psychosis."
EULAR lists major depression among relatively uncommon NPSLE manifestations.
ORPHA:536 SUPPORT Other
"HP:0000716 | Depression | Occasional (29-5%)"
Orphanet classifies depression as occasional in SLE.
Anxiety Disorder Anxiety (HP:0000739)
Show evidence (2 references)
PMID:10211873 SUPPORT Other
"Case definitions including diagnostic criteria, important exclusions, and methods of ascertainment were developed for 19 NPSLE syndromes."
The ACR case-definition paper supports anxiety disorder as part of the standardized diffuse psychiatric NPSLE syndrome framework.
PMID:29846157 SUPPORT Human Clinical
"Q albumin was significantly higher in acute confusional state (ACS) than in non-ACS diffuse NPSLE (anxiety disorder, cognitive dysfunction, mood disorder and psychosis) or in focal NPSLE."
The NPSLE patient cohort explicitly includes anxiety disorder within the diffuse non-ACS NPSLE comparator group.
Headache Headache (HP:0002315)
Show evidence (1 reference)
PMID:18481154 SUPPORT Human Clinical
"Depression (59.4%), headache (46.9%) and cognitive dysfunction (37.5%) were the commonest NPSLE syndromes."
This SLE cohort using ACR NPSLE definitions supports headache as a common NPSLE-classified syndrome in that cohort.
Chorea VERY_RARE Chorea (HP:0002072)
Show evidence (2 references)
ORPHA:536 SUPPORT Other
"HP:0002072 | Chorea | Very rare (<4-1%)"
Orphanet classifies chorea as very rare in SLE.
PMID:18240179 SUPPORT Human Clinical
"Comparison for specific neuropsychiatric manifestations showed a statistically significant association between a persistently positive LAC and chorea (2 patients; P = 0.02)."
The pediatric cohort supports an association between persistent lupus anticoagulant positivity and chorea.
Acute Confusional State VERY_RARE Delirium (HP:0031258)
Show evidence (1 reference)
PMID:20724309 SUPPORT Other
"relatively uncommon (1-5%) are severe cognitive dysfunction, major depression, acute confusional state (ACS), peripheral nervous disorders psychosis."
EULAR lists acute confusional state among relatively uncommon NPSLE manifestations.
Peripheral Neuropathy Peripheral neuropathy (HP:0009830)
Show evidence (1 reference)
PMID:20724309 SUPPORT Other
"Investigations include cerebrospinal fluid analysis (to exclude central nervous system infection), EEG (to diagnose seizure disorder), neuropsychological tests (to assess cognitive dysfunction), nerve conduction studies (for peripheral neuropathy) and MRI"
EULAR specifically includes peripheral neuropathy in NPSLE workup and recommends nerve-conduction studies when indicated.
Demyelinating Syndrome or Myelopathy CNS demyelination (HP:0007305)
Show evidence (1 reference)
PMID:20724309 SUPPORT Other
"Glucocorticoids and immunosuppressive therapy are indicated when NPSLE is thought to reflect an inflammatory process (optic neuritis, transverse myelitis, peripheral neuropathy, refractory seizures, psychosis, ACS) and in the presence of generalised lupus activity."
EULAR identifies optic neuritis and transverse myelitis as inflammatory NPSLE manifestations.
🧬

Genetic Associations

4
TNFAIP3 rs5029939 susceptibility association (Susceptibility polymorphism associated with SLE and neuropsychiatric manifestations)
Show evidence (1 reference)
PMID:35382378 SUPPORT Human Clinical
"Genotype CG was significantly associated with lupus nephritis and neuropsychiatric manifestations (p<0.05)."
This human case-control study directly links TNFAIP3 rs5029939 genotype to neuropsychiatric manifestations among SLE patients.
Pediatric NPSLE immune susceptibility loci (Polygenic susceptibility loci in childhood-onset lupus nephritis with NPSLE)
Show evidence (1 reference)
PMID:39904110 SUPPORT Human Clinical
"CONCLUSION: Our findings indicate that the polymorphisms IL17RA rs2895332, IL23R rs10889677, and FCGR3A rs396991 are significantly associated with the risk of NPSLE in childhood-onset LN."
The pediatric lupus-nephritis cohort directly supports these immune pathway polymorphisms as NPSLE susceptibility loci.
IRF5 and cytokine polymorphism susceptibility (Cytokine and interferon regulatory polymorphisms associated with SLE susceptibility and neuropsychiatric impairment)
Show evidence (1 reference)
PMID:41039983 SUPPORT Human Clinical
"Also, the A allele of the TNFα -238 G/A polymorphism was associated with neuropsychiatric impairment (p = 0.036)"
This cohort links a cytokine-gene polymorphism to neuropsychiatric impairment and supports IRF5/cytokine-gene susceptibility framing.
Broader SLE polygenic risk background (MHC, HLA class II, STAT4, and IRF5 susceptibility background)
Show evidence (1 reference)
PMID:42123548 PARTIAL Other
"Genetic variants in STAT4 and IRF5 exacerbate disease progression by facilitating chronic inflammation. These genetic factors are associated with various clinical outcomes, including renal and neuropsychiatric symptoms."
This review supports broader SLE genetic susceptibility context for neuropsychiatric outcomes, but it does not establish a monogenic NPSLE cause.
💊

Treatments

6
Hydroxychloroquine Background Therapy and Seizure Risk Reduction
Action: Pharmacotherapy NCIT:C15986
Agent: hydroxychloroquine ↗
Hydroxychloroquine is recommended as background therapy for lupus patients when not contraindicated and cohort data suggest antimalarial exposure may reduce seizure risk, a key neuropsychiatric lupus manifestation.
Target Phenotypes: Seizure ↗
Show evidence (2 references)
PMID:37827694 SUPPORT Other
"HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual's risk for flares and retinal toxicity."
Current EULAR SLE management recommendations support hydroxychloroquine as background lupus therapy.
PMID:17875548 SUPPORT Human Clinical
"hydroxychloroquine use (HR = 0.35, 95% CI 0.15 to 0.80, p = 0.0131) were independent predictors of a longer time-to-seizure occurrence."
The LUMINA cohort supports a protective association between hydroxychloroquine exposure and delayed seizure occurrence in SLE.
Glucocorticoid and Cyclophosphamide Therapy for Severe Inflammatory NPSLE
Action: Pharmacotherapy NCIT:C15986
Agent: corticosteroid ↗ cyclophosphamide ↗
High-dose glucocorticoids, often with intravenous cyclophosphamide for severe or refractory inflammatory/autoimmune presentations, are used when NPSLE is attributed to lupus inflammation rather than thrombotic disease.
Mechanism Target:
INHIBITS Autoimmune Neuroinflammation — Glucocorticoids and cytotoxic immunosuppression suppress inflammatory cytokine, lymphocyte, and autoantibody-driven neuroimmune activity.
Show evidence (1 reference)
PMID:26809245 SUPPORT Other
"High-dose glucocorticoids and intravenous cyclophosphamide remain the cornerstone for patients with severe symptoms that are thought to reflect inflammation or an underlying autoimmune process."
The source links this treatment target to inflammatory or autoimmune NPSLE mechanisms.
Show evidence (3 references)
PMID:26809245 SUPPORT Other
"High-dose glucocorticoids and intravenous cyclophosphamide remain the cornerstone for patients with severe symptoms that are thought to reflect inflammation or an underlying autoimmune process."
The review supports glucocorticoids plus cyclophosphamide for severe inflammatory NPSLE.
PMID:18537650 SUPPORT Other
"Severe diffuse CNS manifestations, such as acute confusional state, generalised seizures, mood disorders and psychosis, generally require corticosteroids in the first instance."
This review supports corticosteroids for severe diffuse CNS manifestations.
PMID:18537650 SUPPORT Other
"Pulse intravenous cyclophosphamide therapy may help when more severe manifestations are refractory to corticosteroids and other immunosuppressive agents"
This supports cyclophosphamide escalation for refractory severe NPSLE.
Antithrombotic Therapy for Antiphospholipid-Associated NPSLE
Action: Pharmacotherapy NCIT:C15986
Agent: aspirin ↗ warfarin ↗ heparin ↗
Antiplatelet or anticoagulant therapy is used when neuropsychiatric manifestations are attributed to antiphospholipid-antibody-associated thrombosis, especially thrombotic cerebrovascular disease.
Mechanism Target:
INHIBITS Antiphospholipid-Associated Neurovascular Thrombosis — Antiplatelet and anticoagulant strategies reduce thrombus formation or recurrence in aPL-associated vascular NPSLE.
Show evidence (1 reference)
PMID:20724309 SUPPORT Other
"Antiplatelet/anticoagulation therapy is indicated when manifestations are related to antiphospholipid antibodies, particularly thrombotic CVD."
EULAR directly links antithrombotic treatment to antiphospholipid antibody-associated thrombotic cerebrovascular NPSLE.
Target Phenotypes: Ischemic stroke ↗
Show evidence (2 references)
PMID:20724309 SUPPORT Other
"Antiplatelet/anticoagulation therapy is indicated when manifestations are related to antiphospholipid antibodies, particularly thrombotic CVD."
EULAR supports antithrombotic therapy when NPSLE is aPL/thrombotic.
PMID:26809245 SUPPORT Other
"When symptoms are thought to reflect a thrombotic underlying process, anticoagulation and antiplatelet agents are the mainstay of therapy, especially if antiphospholipid antibodies or antiphospholipid syndrome are present."
The management review supports mechanism-guided antithrombotic therapy.
Steroid-Sparing Maintenance Immunosuppression
Action: Pharmacotherapy NCIT:C15986
Agent: azathioprine ↗ mycophenolate mofetil ↗
Azathioprine or mycophenolate may be considered for mild to moderate inflammatory presentations or maintenance therapy after acute control, depending on the syndrome and overall SLE activity.
Mechanism Target:
INHIBITS Autoimmune Neuroinflammation — Steroid-sparing immunosuppressants reduce ongoing lymphocyte activation and immune-mediated inflammation.
Show evidence (1 reference)
PMID:26809245 SUPPORT Other
"When patients present with mild to moderate NP manifestations, or when maintenance therapy is warranted, azathioprine and mycophenolate may be considered."
The source supports maintenance or mild-to-moderate immunosuppression for inflammatory NPSLE contexts.
Show evidence (1 reference)
PMID:26809245 SUPPORT Other
"When patients present with mild to moderate NP manifestations, or when maintenance therapy is warranted, azathioprine and mycophenolate may be considered."
The review supports azathioprine and mycophenolate for selected mild/moderate or maintenance contexts.
Refractory NPSLE Escalation
Action: Pharmacotherapy NCIT:C15986
Agent: rituximab ↗ human immunoglobulin G ↗
Rituximab, intravenous immunoglobulin, or plasmapheresis may be used in severe inflammatory NPSLE when response to initial glucocorticoid and cyclophosphamide-based treatment is inadequate.
Mechanism Target:
MODULATES Autoimmune Neuroinflammation — B-cell depletion, immune modulation, and antibody removal can be used when severe antibody- or inflammation-mediated NPSLE is refractory.
Show evidence (1 reference)
PMID:26809245 SUPPORT Other
"Rituximab, intravenous immunoglobulins, or plasmapheresis may be used if response is not achieved."
The source supports escalation to immune-targeted therapy when initial inflammatory NPSLE treatment response is inadequate.
Show evidence (3 references)
PMID:26809245 SUPPORT Other
"Rituximab, intravenous immunoglobulins, or plasmapheresis may be used if response is not achieved."
The review supports rituximab, IVIG, or plasmapheresis as escalation options when response is inadequate.
PMID:18537650 PARTIAL Other
"Intravenous immunoglobulins, mycophenolate mofetil, rituximab, intratecal methotrexate and dexametasone deserve further studies to confirm their usefulness in the treatment of neuropsychiatric SLE."
This older review identifies IVIG, mycophenolate, and rituximab as plausible options while emphasizing limited evidence.
PMID:42115580 SUPPORT Human Clinical
"Sixteen of 17 patients (94.1%) achieved significant clinical improvement, while one patient showed partial improvement with reduced seizure frequency."
This refractory NPSLE cohort provides direct clinical support for rituximab as an escalation option, while infection risk still requires monitoring.
Symptomatic Neuropsychiatric Management
Action: supportive care MAXO:0000950
Syndrome-directed treatment such as antipsychotics, antiseizure therapy, antidepressants, and supportive neurologic or psychiatric care is used alongside mechanism-directed immunosuppression or antithrombotic therapy.
Target Phenotypes: Psychosis ↗ Seizure ↗ Depression ↗
Show evidence (2 references)
PMID:26809245 SUPPORT Other
"In the acute setting, management of these patients does not differ from other non-SLE subjects presenting with the same NP manifestation."
This supports standard syndrome-directed acute care before and alongside lupus-specific attribution.
PMID:30375754 SUPPORT Human Clinical
"The following therapies were used during the time of the first psychotic events: corticosteroids in 23 of 28 patients (82.1%)"
The psychosis cohort documents combined immunosuppressive and symptomatic psychiatric treatments in real-world lupus psychosis.
🔬

Biochemical Markers

7
Antiphospholipid antibodies (Positive in subset)
Context: Serum or plasma; includes lupus anticoagulant, anticardiolipin, and anti-beta2 glycoprotein I antibodies.
Show evidence (2 references)
PMID:20724309 SUPPORT Other
"Strong risk factors (at least fivefold increased risk) are previous or concurrent severe NPSLE (for cognitive dysfunction, seizures) and antiphospholipid antibodies (for CVD, seizures, chorea)."
EULAR supports aPL as biomarkers and risk factors for selected NPSLE manifestations.
PMID:18240179 SUPPORT Human Clinical
"At the time of diagnosis, 65% of the children were aCL positive, 41% had anti-beta(2)GPI antibodies, and 26% were LAC positive."
The pediatric SLE cohort quantifies antiphospholipid antibody positivity.
Anti-NMDA-NR2A/B antibodies (Positive in subset)
Context: Serum and/or cerebrospinal fluid.
Show evidence (2 references)
PMID:25081016 SUPPORT Other
"The exact percentage of SLE patients having anti-NMDA-NR2A/B antibodies varies in different studies from 14 to 35%, and in one study such antibodies were found in 81% of patients with diffuse 'Neuropshychiatric SLE', and in 44% of patients with focal 'Neuropshychiatric SLE'."
The review supports anti-NMDA-NR2A/B antibodies as a subset biomarker in SLE and NPSLE.
PMID:25081016 SUPPORT Other
"In some patients, the anti-NMDA-NR2A/B antibodies are present in both the serum and the CSF."
This supports serum and CSF as relevant testing compartments.
Anti-Sm autoantibodies and BBB damage (Elevated in acute confusional state subset)
Context: Serum; associated with Q albumin evidence of BBB dysfunction.
Show evidence (2 references)
PMID:29846157 SUPPORT Human Clinical
"Anti-Sm, but not anti-NR2, anti-P or anticardiolipin, was significantly elevated in ACS compared with the other 2 groups of NPSLE"
The serum/CSF patient study supports anti-Sm elevation in the acute confusional state NPSLE subset.
PMID:29846157 SUPPORT Human Clinical
"Multiple regression analysis confirmed the significant contribution of anti-Sm (p=0.0040), but not anti-NR2 (p=0.5023), anti-P (p=0.2651), or anti-cardiolipin (p=0.6769) in the elevation of Q albumin."
The adjusted analysis links anti-Sm, rather than several other measured autoantibodies, to the Q albumin BBB-dysfunction marker.
Anti-ribosomal P antibodies (Positive in subset)
Context: Serum; associated most strongly with psychiatric manifestations in some cohorts.
Show evidence (2 references)
PMID:18481154 SUPPORT Human Clinical
"aRP was positive in seven (21.9%) patients, all of whom had one or more NPSLE syndromes."
This cohort supports anti-ribosomal P antibody positivity in a subset of NPSLE-classified patients.
PMID:18481154 SUPPORT Human Clinical
"The presence of aRP antibodies positively predicts patients with psychiatric manifestations in general and mood disorders in particular, for which aRP is specific, but not sensitive."
The cohort supports anti-ribosomal P as a psychiatric-manifestation biomarker with limited sensitivity.
Serum S100A8/A9 and MMP-9 (Elevated with cognitive impairment)
Context: Serum.
Show evidence (2 references)
PMID:38332909 SUPPORT Human Clinical
"Serum levels of S100A8/A9 and MMP-9, were significantly higher in patients with CI (p=0.006 and p=0.036, respectively)."
The 290-patient SLE cohort supports S100A8/A9 and MMP-9 elevation with cognitive impairment.
PMID:38332909 SUPPORT Human Clinical
"S100A8/A9 had the greatest discriminatory ability in differentiating between patients with and without CI."
This supports S100A8/A9 as a candidate cognitive-impairment biomarker in SLE.
Blood neurofilament light and glial fibrillary acidic protein (Elevated in active major NPSLE)
Context: Blood, serum, or plasma.
Show evidence (1 reference)
DOI:10.1177/09612033241272961 SUPPORT Human Clinical
"Blood NfL and GFAP levels are elevated in persons with SLE with active major NPSLE compared to disease matched controls and may lower after immunotherapy initiation."
The case-control study supports blood NfL and GFAP as candidate neuronal/glial injury biomarkers in active major NPSLE.
CSF interferon-alpha and neopterin (Elevated in active juvenile CNS NPSLE)
Context: Cerebrospinal fluid.
Show evidence (1 reference)
DOI:10.1007/s10875-022-01407-1 SUPPORT Human Clinical
"CSF IFN-α and neopterin constitute promising biomarkers useful in the diagnosis and monitoring of activity in j-NPSLE."
The pediatric cohort supports CSF interferon-alpha and neopterin as candidate activity biomarkers for juvenile NPSLE.
{ }

Source YAML

click to show 
name: Neuropsychiatric Systemic Lupus Erythematosus
creation_date: "2026-05-16T18:50:15Z"
updated_date: "2026-05-16T19:50:35Z"
category: Autoimmune
parents:
- Systemic Lupus Erythematosus
- Autoimmune Disease
- Neurological Disease
synonyms:
- Neuropsychiatric lupus
- NPSLE
- CNS lupus
- Lupus cerebritis
disease_term:
  preferred_term: neuropsychiatric systemic lupus erythematosus
  term:
    id: MONDO:0007915
    label: systemic lupus erythematosus
description: >-
  Neuropsychiatric systemic lupus erythematosus is the nervous-system
  manifestation spectrum of systemic lupus erythematosus. It includes central
  and peripheral nervous-system syndromes such as seizure, psychosis, cognitive
  dysfunction, cerebrovascular disease, acute confusional state, chorea,
  demyelinating syndromes, and peripheral neuropathy. Attribution is difficult:
  presentations may reflect lupus-driven inflammation, antiphospholipid-related
  thrombosis, both mechanisms, or non-SLE mimics such as infection, metabolic
  disease, medication effects, or primary psychiatric and neurologic disorders.
  No standalone MONDO or Orphanet disease term was found in the local ontology
  resources, so this entry is anchored to the parent systemic lupus
  erythematosus term while preserving the NPSLE preferred term.
definitions:
- name: ACR 1999 neuropsychiatric lupus syndrome framework
  definition_type: CASE_DEFINITION
  description: >-
    The American College of Rheumatology nomenclature provides standardized case
    definitions and ascertainment guidance for 19 neuropsychiatric syndromes
    seen in SLE, spanning central and peripheral nervous-system involvement.
  scope: Patients with SLE and neurologic or psychiatric manifestations.
  criteria_sets:
  - name: Neuropsychiatric syndrome spectrum
    description: >-
      The case-definition framework requires syndrome-specific clinical
      assessment, important exclusions, and appropriate ascertainment methods
      rather than a single pathognomonic laboratory test.
    core_clinical_characteristics:
    - preferred_term: Seizure
      term:
        id: HP:0001250
        label: Seizure
    - preferred_term: Psychosis
      term:
        id: HP:0000709
        label: Psychosis
    - preferred_term: Anxiety
      term:
        id: HP:0000739
        label: Anxiety
    - preferred_term: Cognitive impairment
      term:
        id: HP:0100543
        label: Cognitive impairment
    - preferred_term: Delirium
      term:
        id: HP:0031258
        label: Delirium
      description: Acute confusional state in the ACR/EULAR NPSLE literature.
    - preferred_term: Peripheral neuropathy
      term:
        id: HP:0009830
        label: Peripheral neuropathy
    - preferred_term: CNS demyelination
      term:
        id: HP:0007305
        label: CNS demyelination
      description: Maps the ACR demyelinating-syndrome category.
    evidence:
    - reference: PMID:10211873
      reference_title: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Case definitions including diagnostic criteria, important exclusions,
        and methods of ascertainment were developed for 19 NPSLE syndromes.
      explanation: >-
        This supports the syndrome-spectrum criteria set used to organize the
        ACR neuropsychiatric lupus framework.
  evidence:
  - reference: PMID:10211873
    reference_title: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Case definitions including diagnostic criteria, important exclusions, and
      methods of ascertainment were developed for 19 NPSLE syndromes.
    explanation: >-
      This is the landmark ACR nomenclature and case-definition framework for
      NPSLE syndrome attribution and reporting.
  - reference: PMID:10211873
    reference_title: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The American College of Rheumatology (ACR) Nomenclature for NPSLE provides
      case definitions for 19 neuropsychiatric syndromes seen in SLE, with
      reporting standards and recommendations for laboratory and imaging tests.
    explanation: >-
      The conclusion supports the 19-syndrome framework and its use in clinical
      research and specialist-supported diagnosis.
- name: Attribution and exclusion-based diagnosis
  definition_type: DIAGNOSTIC_CRITERIA
  description: >-
    Suspected NPSLE is first evaluated like the same neurologic or psychiatric
    syndrome in a patient without SLE. Attribution to lupus follows exclusion of
    non-SLE causes and assessment for inflammatory, autoimmune, thrombotic, or
    mixed mechanisms.
  scope: Diagnostic workup of new neurologic or psychiatric events in patients with SLE.
  criteria_sets:
  - name: EULAR diagnostic workup
    description: >-
      Workup includes targeted studies such as CSF analysis, EEG,
      neuropsychological testing, nerve-conduction studies, and MRI according to
      the presenting syndrome.
    minimum_required: 1
    evidence:
    - reference: PMID:20724309
      reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The diagnostic work-up of suspected NPSLE is comparable to that in
        patients without SLE who present with the same manifestations, and aims
        to exclude causes unrelated to SLE.
      explanation: >-
        EULAR explicitly frames diagnosis as syndrome-based evaluation and
        exclusion of non-SLE causes.
  evidence:
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Due to the lack of a gold standard, the attribution of NP symptoms to SLE
      represents a clinical challenge that obligates the strict exclusion of any
      other potential cause.
    explanation: >-
      The management review supports the attribution-and-exclusion diagnostic
      framing used here.
has_subtypes:
- name: Inflammatory or autoimmune NPSLE
  description: >-
    NPSLE manifestations attributed primarily to lupus-driven inflammation or
    autoimmunity, including optic neuritis, transverse myelitis, peripheral
    neuropathy, refractory seizures, psychosis, and acute confusional state,
    especially when generalized lupus activity is present.
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Glucocorticoids and immunosuppressive therapy are indicated when NPSLE is
      thought to reflect an inflammatory process (optic neuritis, transverse
      myelitis, peripheral neuropathy, refractory seizures, psychosis, ACS) and
      in the presence of generalised lupus activity.
    explanation: >-
      EULAR distinguishes inflammatory-process NPSLE manifestations that warrant
      glucocorticoids and immunosuppression.
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      High-dose glucocorticoids and intravenous cyclophosphamide remain the
      cornerstone for patients with severe symptoms that are thought to reflect
      inflammation or an underlying autoimmune process.
    explanation: >-
      This treatment distinction supports an inflammatory/autoimmune subtype
      concept used in clinical decision-making.
- name: Antiphospholipid-associated thrombotic NPSLE
  description: >-
    Focal or vascular neuropsychiatric lupus manifestations driven by
    antiphospholipid-antibody-associated thrombosis or ischemia, especially
    cerebrovascular disease, seizures, and chorea.
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Strong risk factors (at least fivefold increased risk) are previous or
      concurrent severe NPSLE (for cognitive dysfunction, seizures) and
      antiphospholipid antibodies (for CVD, seizures, chorea).
    explanation: >-
      EULAR identifies antiphospholipid antibodies as strong risk factors for
      vascular and selected neurologic NPSLE manifestations.
  - reference: PMID:18537650
    reference_title: Therapeutic approach to neuropsychiatric systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Focal CNS manifestations, particularly TIA and stroke, are associated with
      the presence of antiphospholipid antibodies (aPL).
    explanation: >-
      This review supports a focal thrombotic/aPL-associated clinical subtype.
epidemiology:
- name: Neuropsychiatric event burden in an international SLE inception cohort
  description: >-
    In the SLICC inception cohort, any neuropsychiatric event was common, but
    only a subset of events were attributed to SLE depending on attribution
    model stringency.
  evidence:
  - reference: PMID:30375754
    reference_title: "Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NP events (≥1) occurred in 951 of 1,826 patients (52.1%), and 488 of
      1,826 patients (26.7%) had ≥2 events during the study period.
    explanation: >-
      The inception cohort quantifies neuropsychiatric events among SLE
      patients, emphasizing the event burden that enters NPSLE attribution.
  - reference: PMID:30375754
    reference_title: "Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The proportion of NP events attributed to SLE varied from 17.8%
      (attribution model A) to 31.1% (attribution model B) and occurred in 13.3%
      of patients (model A) to 21.1% of patients (model B).
    explanation: >-
      These data support the distinction between all NP events in SLE and events
      attributed to SLE.
- name: EULAR frequency categories for major NPSLE manifestations
  description: >-
    EULAR summarizes cerebrovascular disease and seizures as common cumulative
    manifestations, while severe cognitive dysfunction, major depression, acute
    confusional state, peripheral nervous disorders, and psychosis are less
    common.
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Common (cumulative incidence > 5%) manifestations include cerebrovascular
      disease (CVD) and seizures; relatively uncommon (1-5%) are severe
      cognitive dysfunction, major depression, acute confusional state (ACS),
      peripheral nervous disorders psychosis.
    explanation: >-
      This provides frequency bands for the major NPSLE manifestations encoded
      below.
pathophysiology:
- name: Autoimmune Neuroinflammation
  description: >-
    Systemic lupus autoimmunity can extend to the nervous system through
    autoantibody production, immune-complex and complement activation,
    type I interferon signaling, cytokine-mediated inflammation, and
    intrathecal immune activation, producing diffuse or focal neuropsychiatric
    syndromes.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: choroid plexus
    modifier: ABNORMAL
    term:
      id: UBERON:0001886
      label: choroid plexus
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: immunoglobulin production
    term:
      id: GO:0002377
      label: immunoglobulin production
    modifier: INCREASED
  - preferred_term: neuroinflammatory response
    term:
      id: GO:0150076
      label: neuroinflammatory response
    modifier: INCREASED
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
    modifier: INCREASED
  - preferred_term: type I interferon-mediated signaling pathway
    term:
      id: GO:0060337
      label: type I interferon-mediated signaling pathway
    modifier: INCREASED
  downstream:
  - target: Blood-Brain Barrier Disruption
    description: >-
      Inflammatory mediators and complement can impair barrier integrity,
      allowing neuropathic antibodies and soluble mediators to reach brain
      parenchyma.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26809245
      reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Among them, anti-endothelial cell antibodies, complement components,
        cytokines and chemokines, and environmental mediators have an essential
        role
      explanation: >-
        The review links inflammatory and complement mediators to BBB-integrity
        modulation in NPSLE.
  evidence:
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In clinical practice, therapies are directed to a presumptive
      pathophysiologic process (inflammatory, thrombotic, or both).
    explanation: >-
      The review supports inflammatory and thrombotic mechanism clusters as the
      practical mechanistic framing for NPSLE.
  - reference: PMID:41989680
    reference_title: Pathogenesis and therapeutic strategies for neuropsychiatric lupus centered on innate immune activation.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      aberrant activation of innate immunity by self-nucleic acids and
      consequent overproduction of Type I interferons (IFN-I) constitute a
      central pathogenic axis in NPSLE.
    explanation: >-
      This review supports type I interferon-driven innate immune activation as
      a central inflammatory axis in NPSLE.
  - reference: PMID:37369340
    reference_title: Spatial enrichment of the type 1 interferon signature in the brain of a neuropsychiatric lupus murine model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      interferon-stimulated genes (ISGs) were among the most highly upregulated
      genes in both regions and that gene pathways involved in cellular
      interaction and neuronal development were generally repressed among
      astrocytes, oligodendrocytes, and neurons.
    explanation: >-
      The mouse spatial transcriptomics study supports CNS interferon signaling
      as a mechanistic contributor to neuropsychiatric lupus phenotypes.
  - reference: PMID:38531610
    reference_title: Characterisation of choroid plexus-infiltrating T cells reveals novel therapeutic targets in murine neuropsychiatric lupus.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Systemic blockade of VLA-4, the cognate ligand of VCAM, resulted in
      significant resolution of the ChP immune cell infiltration and attenuation
      of the depressive phenotype.
    explanation: >-
      This supports choroid-plexus immune-cell infiltration as a tractable
      neuroimmune mechanism in murine NPSLE.
- name: Blood-Brain Barrier Disruption
  description: >-
    Disruption of the blood-brain barrier permits circulating neuropathic
    autoantibodies, complement components, cytokines, and chemokines to enter
    CNS tissue and interact with neurons, glia, and endothelial cells.
  locations:
  - preferred_term: blood brain barrier
    modifier: ABNORMAL
    term:
      id: UBERON:0000120
      label: blood brain barrier
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: maintenance of blood-brain barrier
    modifier: DECREASED
    term:
      id: GO:0035633
      label: maintenance of blood-brain barrier
  - preferred_term: astrocyte activation
    modifier: INCREASED
    term:
      id: GO:0048143
      label: astrocyte activation
  downstream:
  - target: Anti-NMDA-NR2A/B Neuronal Excitotoxicity
    description: >-
      Barrier disruption can allow anti-NR2/glutamate-receptor antibodies to
      access neuronal targets and alter synaptic signaling or neuronal survival.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26809245
      reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        It has been proposed that a disruption of the integrity of the BBB may
        have a potential pathogenic role in NPSLE since this may permit the
        influx of neuropathic antibodies across the BBB.
      explanation: >-
        This supports the edge from BBB disruption to CNS entry of neuropathic
        antibodies.
  evidence:
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The BBB is a network of endothelial cells and pericyte and astrocyte
      projections that regulates the entry of soluble molecules and cells into
      the brain parenchyma.
    explanation: >-
      The review defines the anatomical and cellular barrier interface relevant
      to NPSLE.
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      It has been proposed that a disruption of the integrity of the BBB may
      have a potential pathogenic role in NPSLE since this may permit the
      influx of neuropathic antibodies across the BBB.
    explanation: >-
      This directly supports BBB disruption as a pathogenic step in NPSLE.
  - reference: PMID:29846157
    reference_title: Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CONCLUSIONS: The data demonstrate that serum anti-Sm antibodies play a
      most important role in the disruption of BBB in NPSLE.
    explanation: >-
      The patient serum/CSF study links anti-Sm autoantibodies to BBB
      dysfunction as measured by Q albumin.
- name: Anti-NMDA-NR2A/B Neuronal Excitotoxicity
  description: >-
    A subset of SLE patients have anti-NMDA-NR2A/B glutamate-receptor
    antibodies. When these antibodies reach CNS targets, they can alter NMDA
    receptor signaling, injure neurons, and contribute to cognitive,
    behavioral, mood, seizure, or psychiatric manifestations.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: glutamate receptor signaling pathway
    modifier: ABNORMAL
    term:
      id: GO:0007215
      label: glutamate receptor signaling pathway
  - preferred_term: chemical synaptic transmission
    modifier: ABNORMAL
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  - preferred_term: positive regulation of calcium ion transport
    modifier: INCREASED
    term:
      id: GO:0051928
      label: positive regulation of calcium ion transport
  evidence:
  - reference: PMID:25081016
    reference_title: "Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Some of the anti-NMDA-NR2A/B antibodies associate with
      neuropsychiatric/cognitive/behavior/mood impairments in SLE patients,
      while others do not.
    explanation: >-
      The review supports anti-NMDA-NR2A/B antibodies as a heterogeneous but
      relevant autoantibody class in NPSLE.
  - reference: PMID:25081016
    reference_title: "Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The anti-NMDA-NR2A/B antibodies can undoubtedly be very pathogenic, since
      they can kill neurons by activating NMDA receptors and inducing
      'Excitotoxicity', damage the brain
    explanation: >-
      This supports neuronal excitotoxicity as a downstream mechanism for a
      subset of anti-NR2 antibody-positive disease.
- name: Antiphospholipid-Associated Neurovascular Thrombosis
  description: >-
    Antiphospholipid antibodies promote neurovascular risk through endothelial,
    platelet, coagulation, and complement-related prothrombotic mechanisms,
    producing ischemic or focal NPSLE manifestations such as cerebrovascular
    disease, seizures, and chorea.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: blood coagulation
    modifier: INCREASED
    term:
      id: GO:0007596
      label: blood coagulation
  - preferred_term: platelet activation
    modifier: INCREASED
    term:
      id: GO:0030168
      label: platelet activation
  - preferred_term: complement activation
    modifier: INCREASED
    term:
      id: GO:0006956
      label: complement activation
  downstream:
  - target: Ischemic Stroke
    description: >-
      Prothrombotic aPL-associated vascular injury can culminate in thrombotic
      cerebrovascular disease.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20724309
      reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Antiplatelet/anticoagulation therapy is indicated when manifestations
        are related to antiphospholipid antibodies, particularly thrombotic CVD.
      explanation: >-
        The therapeutic recommendation supports the thrombotic/aPL mechanism
        leading to cerebrovascular disease.
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Strong risk factors (at least fivefold increased risk) are previous or
      concurrent severe NPSLE (for cognitive dysfunction, seizures) and
      antiphospholipid antibodies (for CVD, seizures, chorea).
    explanation: >-
      This supports aPL-associated vascular and neurologic manifestations as a
      distinct mechanistic cluster.
  - reference: PMID:18240179
    reference_title: A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our data suggest an association between LAC and cerebrovascular disease at
      the time of SLE diagnosis and chorea over the disease course, but not
      between aPL and other neuropsychiatric manifestations.
    explanation: >-
      The pediatric cohort supports lupus anticoagulant association with
      cerebrovascular disease and chorea.
phenotypes:
- category: Neuropsychiatric
  name: Cerebrovascular Disease
  frequency: OCCASIONAL
  description: >-
    Focal vascular NPSLE includes thrombotic cerebrovascular disease and stroke,
    particularly when antiphospholipid antibodies are present.
  phenotype_term:
    preferred_term: Ischemic stroke
    term:
      id: HP:0002140
      label: Ischemic stroke
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Common (cumulative incidence > 5%) manifestations include cerebrovascular
      disease (CVD) and seizures
    explanation: >-
      EULAR classifies cerebrovascular disease as a common cumulative NPSLE
      manifestation.
  - reference: PMID:34468807
    reference_title: "An unexpected cause of chorea in an adolescent girl: systemic lupus erythematosus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Central nervous system involvement defined as neuropsychiatric lupus
      presents wide clinical findings varying from stroke and seizures to
      psychosis and cognitive dysfunction.
    explanation: >-
      This case report review statement supports stroke as part of the NPSLE
      phenotype spectrum.
- category: Neuropsychiatric
  name: Seizure
  frequency: OCCASIONAL
  description: >-
    Seizures are a recognized NPSLE manifestation and may be related to
    inflammatory, thrombotic, vascular, or antibody-associated mechanisms.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Common (cumulative incidence > 5%) manifestations include cerebrovascular
      disease (CVD) and seizures
    explanation: >-
      EULAR classifies seizures as a common cumulative NPSLE manifestation.
  - reference: PMID:33626435
    reference_title: "Seizures in systemic lupus erythematosus: A scoping review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The prevalence of explicit episodes of seizures among SLE patients, varies
      from 2 to 8%.
    explanation: >-
      The scoping review provides an SLE-level seizure prevalence range.
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Occasional (29-5%)"
    explanation: >-
      Orphanet classifies seizure as an occasional phenotype in systemic lupus
      erythematosus.
- category: Neuropsychiatric
  name: Psychosis
  frequency: VERY_RARE
  description: >-
    Lupus psychosis is an uncommon acute psychiatric NPSLE manifestation that is
    attributed to SLE after exclusion of primary psychotic, substance-induced,
    medication-related, and reactive psychiatric disorders.
  phenotype_term:
    preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
  evidence:
  - reference: PMID:30375754
    reference_title: "Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among 28 of 1,826 patients with psychosis (1.53%), 26 of 28 (93%) had a
      single psychotic event, while 1 patient had 2 discrete events and 1
      patient had 3 discrete events.
    explanation: >-
      The large international inception cohort supports psychosis as a rare
      NPSLE event.
  - reference: PMID:30375754
    reference_title: "Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Using a well‐defined process for determining attribution, we confirmed
      that the majority of psychotic events were due to SLE.
    explanation: >-
      The cohort supports lupus attribution for most psychotic events under the
      broader attribution model.
- category: Neuropsychiatric
  name: Cognitive Impairment
  description: >-
    Cognitive dysfunction is part of the NPSLE spectrum, but severity and lupus
    attribution vary across studies and require objective cognitive assessment
    and exclusion of alternative contributors.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:10211873
    reference_title: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A short neuropsychological test battery for the diagnosis of cognitive
      deficits was proposed.
    explanation: >-
      The ACR case-definition paper supports formal neuropsychological
      evaluation of NPSLE cognitive dysfunction.
  - reference: PMID:38332909
    reference_title: Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 290 patients, 40% (n=116) had CI."
    explanation: >-
      This large SLE cohort quantifies cognitive impairment and supports its
      clinical relevance, though it is not itself an NPSLE-attribution study.
- category: Neuropsychiatric
  name: Depression
  frequency: OCCASIONAL
  description: >-
    Major depression and depressive symptoms may occur in SLE and are included
    in the NPSLE syndrome framework after attribution and exclusion of common
    non-SLE causes.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      relatively uncommon (1-5%) are severe cognitive dysfunction, major
      depression, acute confusional state (ACS), peripheral nervous disorders
      psychosis.
    explanation: >-
      EULAR lists major depression among relatively uncommon NPSLE
      manifestations.
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000716 | Depression | Occasional (29-5%)"
    explanation: Orphanet classifies depression as occasional in SLE.
- category: Neuropsychiatric
  name: Anxiety Disorder
  description: >-
    Anxiety disorder is an ACR-defined diffuse psychiatric NPSLE syndrome and
    requires attribution after exclusion of primary anxiety, medication-related,
    metabolic, infectious, and reactive causes.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:10211873
    reference_title: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Case definitions including diagnostic criteria, important exclusions, and
      methods of ascertainment were developed for 19 NPSLE syndromes.
    explanation: >-
      The ACR case-definition paper supports anxiety disorder as part of the
      standardized diffuse psychiatric NPSLE syndrome framework.
  - reference: PMID:29846157
    reference_title: Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Q albumin was significantly higher in acute confusional state (ACS) than
      in non-ACS diffuse NPSLE (anxiety disorder, cognitive dysfunction, mood
      disorder and psychosis) or in focal NPSLE.
    explanation: >-
      The NPSLE patient cohort explicitly includes anxiety disorder within the
      diffuse non-ACS NPSLE comparator group.
- category: Neuropsychiatric
  name: Headache
  description: >-
    Headache is part of the ACR NPSLE syndrome list, but isolated headache is a
    common general-population symptom and requires careful attribution.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:18481154
    reference_title: Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Depression (59.4%), headache (46.9%) and cognitive dysfunction (37.5%)
      were the commonest NPSLE syndromes.
    explanation: >-
      This SLE cohort using ACR NPSLE definitions supports headache as a common
      NPSLE-classified syndrome in that cohort.
- category: Neuropsychiatric
  name: Chorea
  frequency: VERY_RARE
  description: >-
    Chorea is a rare movement-disorder manifestation of NPSLE and is associated
    with antiphospholipid antibodies in pediatric and broader NPSLE literature.
  phenotype_term:
    preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  evidence:
  - reference: ORPHA:536
    reference_title: "Systemic lupus erythematosus (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002072 | Chorea | Very rare (<4-1%)"
    explanation: Orphanet classifies chorea as very rare in SLE.
  - reference: PMID:18240179
    reference_title: A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Comparison for specific neuropsychiatric manifestations showed a
      statistically significant association between a persistently positive LAC
      and chorea (2 patients; P = 0.02).
    explanation: >-
      The pediatric cohort supports an association between persistent lupus
      anticoagulant positivity and chorea.
- category: Neuropsychiatric
  name: Acute Confusional State
  frequency: VERY_RARE
  description: >-
    Acute confusional state is a severe diffuse NPSLE manifestation and overlaps
    clinically with delirium or encephalopathy.
  phenotype_term:
    preferred_term: Delirium
    term:
      id: HP:0031258
      label: Delirium
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      relatively uncommon (1-5%) are severe cognitive dysfunction, major
      depression, acute confusional state (ACS), peripheral nervous disorders
      psychosis.
    explanation: >-
      EULAR lists acute confusional state among relatively uncommon NPSLE
      manifestations.
- category: Neuropsychiatric
  name: Peripheral Neuropathy
  description: >-
    Peripheral nervous-system disorders are included within NPSLE and may be
    inflammatory, immune-mediated, or attributable to non-SLE mimics depending
    on clinical context and testing.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Investigations include cerebrospinal fluid analysis (to exclude central
      nervous system infection), EEG (to diagnose seizure disorder),
      neuropsychological tests (to assess cognitive dysfunction), nerve
      conduction studies (for peripheral neuropathy) and MRI
    explanation: >-
      EULAR specifically includes peripheral neuropathy in NPSLE workup and
      recommends nerve-conduction studies when indicated.
- category: Neuropsychiatric
  name: Demyelinating Syndrome or Myelopathy
  description: >-
    Demyelinating syndromes, optic neuritis, and transverse myelitis are severe
    inflammatory NPSLE presentations and enter the differential against other
    inflammatory demyelinating diseases.
  phenotype_term:
    preferred_term: CNS demyelination
    term:
      id: HP:0007305
      label: CNS demyelination
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Glucocorticoids and immunosuppressive therapy are indicated when NPSLE is
      thought to reflect an inflammatory process (optic neuritis, transverse
      myelitis, peripheral neuropathy, refractory seizures, psychosis, ACS) and
      in the presence of generalised lupus activity.
    explanation: >-
      EULAR identifies optic neuritis and transverse myelitis as inflammatory
      NPSLE manifestations.
biochemical:
- name: Antiphospholipid antibodies
  presence: Positive in subset
  context: Serum or plasma; includes lupus anticoagulant, anticardiolipin, and anti-beta2 glycoprotein I antibodies.
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Strong risk factors (at least fivefold increased risk) are previous or
      concurrent severe NPSLE (for cognitive dysfunction, seizures) and
      antiphospholipid antibodies (for CVD, seizures, chorea).
    explanation: >-
      EULAR supports aPL as biomarkers and risk factors for selected NPSLE
      manifestations.
  - reference: PMID:18240179
    reference_title: A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At the time of diagnosis, 65% of the children were aCL positive, 41% had
      anti-beta(2)GPI antibodies, and 26% were LAC positive.
    explanation: >-
      The pediatric SLE cohort quantifies antiphospholipid antibody positivity.
- name: Anti-NMDA-NR2A/B antibodies
  presence: Positive in subset
  context: Serum and/or cerebrospinal fluid.
  evidence:
  - reference: PMID:25081016
    reference_title: "Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The exact percentage of SLE patients having anti-NMDA-NR2A/B antibodies
      varies in different studies from 14 to 35%, and in one study such
      antibodies were found in 81% of patients with diffuse 'Neuropshychiatric
      SLE', and in 44% of patients with focal 'Neuropshychiatric SLE'.
    explanation: >-
      The review supports anti-NMDA-NR2A/B antibodies as a subset biomarker in
      SLE and NPSLE.
  - reference: PMID:25081016
    reference_title: "Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In some patients, the anti-NMDA-NR2A/B antibodies are present in both the
      serum and the CSF.
    explanation: >-
      This supports serum and CSF as relevant testing compartments.
- name: Anti-Sm autoantibodies and BBB damage
  presence: Elevated in acute confusional state subset
  context: Serum; associated with Q albumin evidence of BBB dysfunction.
  evidence:
  - reference: PMID:29846157
    reference_title: Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Anti-Sm, but not anti-NR2, anti-P or anticardiolipin, was significantly
      elevated in ACS compared with the other 2 groups of NPSLE
    explanation: >-
      The serum/CSF patient study supports anti-Sm elevation in the acute
      confusional state NPSLE subset.
  - reference: PMID:29846157
    reference_title: Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Multiple regression analysis confirmed the significant contribution of
      anti-Sm (p=0.0040), but not anti-NR2 (p=0.5023), anti-P (p=0.2651), or
      anti-cardiolipin (p=0.6769) in the elevation of Q albumin.
    explanation: >-
      The adjusted analysis links anti-Sm, rather than several other measured
      autoantibodies, to the Q albumin BBB-dysfunction marker.
- name: Anti-ribosomal P antibodies
  presence: Positive in subset
  context: Serum; associated most strongly with psychiatric manifestations in some cohorts.
  evidence:
  - reference: PMID:18481154
    reference_title: Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aRP was positive in seven (21.9%) patients, all of whom had one or more
      NPSLE syndromes.
    explanation: >-
      This cohort supports anti-ribosomal P antibody positivity in a subset of
      NPSLE-classified patients.
  - reference: PMID:18481154
    reference_title: Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The presence of aRP antibodies positively predicts patients with
      psychiatric manifestations in general and mood disorders in particular,
      for which aRP is specific, but not sensitive.
    explanation: >-
      The cohort supports anti-ribosomal P as a psychiatric-manifestation
      biomarker with limited sensitivity.
- name: Serum S100A8/A9 and MMP-9
  presence: Elevated with cognitive impairment
  context: Serum.
  evidence:
  - reference: PMID:38332909
    reference_title: Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Serum levels of S100A8/A9 and MMP-9, were significantly higher in
      patients with CI (p=0.006 and p=0.036, respectively).
    explanation: >-
      The 290-patient SLE cohort supports S100A8/A9 and MMP-9 elevation with
      cognitive impairment.
  - reference: PMID:38332909
    reference_title: Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      S100A8/A9 had the greatest discriminatory ability in differentiating
      between patients with and without CI.
    explanation: >-
      This supports S100A8/A9 as a candidate cognitive-impairment biomarker in
      SLE.
- name: Blood neurofilament light and glial fibrillary acidic protein
  presence: Elevated in active major NPSLE
  context: Blood, serum, or plasma.
  evidence:
  - reference: DOI:10.1177/09612033241272961
    reference_title: Blood-based biomarkers of neuronal and glial injury in active major neuropsychiatric systemic lupus erythematosus
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Blood NfL and GFAP levels are elevated in persons with SLE with active
      major NPSLE compared to disease matched controls and may lower after
      immunotherapy initiation.
    explanation: >-
      The case-control study supports blood NfL and GFAP as candidate
      neuronal/glial injury biomarkers in active major NPSLE.
- name: CSF interferon-alpha and neopterin
  presence: Elevated in active juvenile CNS NPSLE
  context: Cerebrospinal fluid.
  evidence:
  - reference: DOI:10.1007/s10875-022-01407-1
    reference_title: "Juvenile Neuropsychiatric Systemic Lupus Erythematosus: Identification of Novel Central Neuroinflammation Biomarkers"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CSF IFN-α and neopterin constitute promising biomarkers useful in the
      diagnosis and monitoring of activity in j-NPSLE.
    explanation: >-
      The pediatric cohort supports CSF interferon-alpha and neopterin as
      candidate activity biomarkers for juvenile NPSLE.
genetic:
- name: TNFAIP3 rs5029939 susceptibility association
  gene_term:
    preferred_term: TNFAIP3
    term:
      id: hgnc:11896
      label: TNFAIP3
  association: Susceptibility polymorphism associated with SLE and neuropsychiatric manifestations
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  features: >-
    TNFAIP3 encodes A20, a negative regulator of NF-kB signaling. The
    rs5029939 CG genotype was associated with SLE susceptibility and with
    neuropsychiatric manifestations in one case-control cohort.
  evidence:
  - reference: PMID:35382378
    reference_title: "Association of <em>TNFAIP3</em> gene polymorphism (<em>rs5029939</em>) with susceptibility and clinical phenotype of systemic lupus erythematosus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genotype CG was significantly associated with lupus nephritis and
      neuropsychiatric manifestations (p<0.05).
    explanation: >-
      This human case-control study directly links TNFAIP3 rs5029939 genotype
      to neuropsychiatric manifestations among SLE patients.
- name: Pediatric NPSLE immune susceptibility loci
  association: Polygenic susceptibility loci in childhood-onset lupus nephritis with NPSLE
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  features: >-
    IL17RA rs2895332, IL23R rs10889677, and FCGR3A rs396991 were associated
    with NPSLE risk in pediatric patients with lupus nephritis, supporting an
    immune-pathway susceptibility component rather than a monogenic cause.
  evidence:
  - reference: PMID:39904110
    reference_title: IL-17A, IL-23R, FCGR3A are associated with neuropsychiatric systemic lupus erythematosus susceptibility in pediatric patients with lupus nephritis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CONCLUSION: Our findings indicate that the polymorphisms IL17RA
      rs2895332, IL23R rs10889677, and FCGR3A rs396991 are significantly
      associated with the risk of NPSLE in childhood-onset LN.
    explanation: >-
      The pediatric lupus-nephritis cohort directly supports these immune
      pathway polymorphisms as NPSLE susceptibility loci.
- name: IRF5 and cytokine polymorphism susceptibility
  association: Cytokine and interferon regulatory polymorphisms associated with SLE susceptibility and neuropsychiatric impairment
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  features: >-
    IRF5 and cytokine-gene polymorphisms contribute to SLE susceptibility in
    cohort studies; TNF-alpha -238 G/A was associated with neuropsychiatric
    impairment in an Algerian SLE cohort.
  evidence:
  - reference: PMID:41039983
    reference_title: Cytokine and IRF5 Gene Polymorphisms Associated With Susceptibility and Organ Damage in Systemic Lupus Erythematosus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Also, the A allele of the TNFα -238 G/A polymorphism was associated
      with neuropsychiatric impairment (p = 0.036)
    explanation: >-
      This cohort links a cytokine-gene polymorphism to neuropsychiatric
      impairment and supports IRF5/cytokine-gene susceptibility framing.
- name: Broader SLE polygenic risk background
  association: MHC, HLA class II, STAT4, and IRF5 susceptibility background
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  features: >-
    NPSLE occurs on the broader polygenic SLE susceptibility background. MHC/HLA
    class II, STAT4, and IRF5 variants are reported risk or progression loci,
    with narrative-review evidence linking genetic factors to renal and
    neuropsychiatric clinical outcomes.
  evidence:
  - reference: PMID:42123548
    reference_title: "Genetic Polymorphisms in Systemic Lupus Erythematosus and Their Clinical Implications: A Narrative Review."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      Genetic variants in STAT4 and IRF5 exacerbate disease progression by
      facilitating chronic inflammation. These genetic factors are associated
      with various clinical outcomes, including renal and neuropsychiatric
      symptoms.
    explanation: >-
      This review supports broader SLE genetic susceptibility context for
      neuropsychiatric outcomes, but it does not establish a monogenic NPSLE
      cause.
diagnosis:
- name: Syndrome-specific exclusion workup
  description: >-
    NPSLE diagnosis requires a syndrome-specific workup similar to that used in
    non-SLE patients, with exclusion of infection, metabolic disease, drug
    effects, primary psychiatric disease, and other neurologic mimics before
    lupus attribution.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  results: >-
    Workup supports a neurologic or psychiatric syndrome and excludes non-SLE
    causes before attribution to inflammatory, thrombotic, or mixed NPSLE.
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The diagnostic work-up of suspected NPSLE is comparable to that in
      patients without SLE who present with the same manifestations, and aims to
      exclude causes unrelated to SLE.
    explanation: >-
      This is the core EULAR diagnostic principle for suspected NPSLE.
- name: Neurodiagnostic testing
  description: >-
    CSF analysis, EEG, neuropsychological testing, nerve-conduction studies, and
    MRI are selected according to the presenting manifestation.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  results: >-
    CSF excludes infection or supports inflammation; EEG evaluates seizure
    disorder; neuropsychological tests characterize cognitive dysfunction; nerve
    conduction supports peripheral neuropathy; MRI evaluates vascular,
    inflammatory, demyelinating, or structural mimics.
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Investigations include cerebrospinal fluid analysis (to exclude central
      nervous system infection), EEG (to diagnose seizure disorder),
      neuropsychological tests (to assess cognitive dysfunction), nerve
      conduction studies (for peripheral neuropathy) and MRI
    explanation: >-
      EULAR lists the major neurodiagnostic tests and their syndrome-specific
      roles.
- name: Autoantibody and inflammatory biomarker assessment
  description: >-
    Serologic and CSF testing may include antiphospholipid antibodies,
    anti-ribosomal P antibodies, anti-NMDA-NR2 antibodies, complement and SLE
    activity markers, and emerging neuroinflammatory or injury biomarkers.
  diagnosis_term:
    preferred_term: serology testing
    term:
      id: MAXO:0000609
      label: serology testing
  results: >-
    Antiphospholipid antibodies support thrombotic attribution; anti-ribosomal P
    or anti-NMDA-NR2 antibodies may support selected psychiatric or cognitive
    endophenotypes but are not standalone diagnostic tests.
  evidence:
  - reference: PMID:30375754
    reference_title: "Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Plasma lupus anticoagulant, serum IgG anticardiolipin,
      anti–β2‐glycoprotein I, anti–ribosomal P (anti‐P), and anti–NR2 glutamate
      receptor antibodies were measured at the Oklahoma Medical Research
      Foundation
    explanation: >-
      The SLICC psychosis cohort demonstrates the relevant autoantibody panel
      used in NPSLE attribution research.
treatments:
- name: Hydroxychloroquine Background Therapy and Seizure Risk Reduction
  description: >-
    Hydroxychloroquine is recommended as background therapy for lupus patients
    when not contraindicated and cohort data suggest antimalarial exposure may
    reduce seizure risk, a key neuropsychiatric lupus manifestation.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: hydroxychloroquine
      term:
        id: CHEBI:5801
        label: hydroxychloroquine
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:37827694
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus: 2023 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      HCQ is recommended for all patients with lupus at a target dose 5 mg/kg
      real body weight/day, considering the individual's risk for flares and
      retinal toxicity.
    explanation: >-
      Current EULAR SLE management recommendations support hydroxychloroquine
      as background lupus therapy.
  - reference: PMID:17875548
    reference_title: "Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      hydroxychloroquine use (HR = 0.35, 95% CI 0.15 to 0.80, p = 0.0131) were
      independent predictors of a longer time-to-seizure occurrence.
    explanation: >-
      The LUMINA cohort supports a protective association between
      hydroxychloroquine exposure and delayed seizure occurrence in SLE.
- name: Glucocorticoid and Cyclophosphamide Therapy for Severe Inflammatory NPSLE
  description: >-
    High-dose glucocorticoids, often with intravenous cyclophosphamide for
    severe or refractory inflammatory/autoimmune presentations, are used when
    NPSLE is attributed to lupus inflammation rather than thrombotic disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: corticosteroid
      term:
        id: CHEBI:50858
        label: corticosteroid
    - preferred_term: cyclophosphamide
      term:
        id: CHEBI:4027
        label: cyclophosphamide
  target_mechanisms:
  - target: Autoimmune Neuroinflammation
    treatment_effect: INHIBITS
    description: >-
      Glucocorticoids and cytotoxic immunosuppression suppress inflammatory
      cytokine, lymphocyte, and autoantibody-driven neuroimmune activity.
    evidence:
    - reference: PMID:26809245
      reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        High-dose glucocorticoids and intravenous cyclophosphamide remain the
        cornerstone for patients with severe symptoms that are thought to
        reflect inflammation or an underlying autoimmune process.
      explanation: >-
        The source links this treatment target to inflammatory or autoimmune
        NPSLE mechanisms.
  evidence:
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      High-dose glucocorticoids and intravenous cyclophosphamide remain the
      cornerstone for patients with severe symptoms that are thought to reflect
      inflammation or an underlying autoimmune process.
    explanation: >-
      The review supports glucocorticoids plus cyclophosphamide for severe
      inflammatory NPSLE.
  - reference: PMID:18537650
    reference_title: Therapeutic approach to neuropsychiatric systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Severe diffuse CNS manifestations, such as acute confusional state,
      generalised seizures, mood disorders and psychosis, generally require
      corticosteroids in the first instance.
    explanation: >-
      This review supports corticosteroids for severe diffuse CNS
      manifestations.
  - reference: PMID:18537650
    reference_title: Therapeutic approach to neuropsychiatric systemic lupus erythematosus.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Pulse intravenous cyclophosphamide therapy may help when more severe
      manifestations are refractory to corticosteroids and other
      immunosuppressive agents
    explanation: >-
      This supports cyclophosphamide escalation for refractory severe NPSLE.
- name: Antithrombotic Therapy for Antiphospholipid-Associated NPSLE
  description: >-
    Antiplatelet or anticoagulant therapy is used when neuropsychiatric
    manifestations are attributed to antiphospholipid-antibody-associated
    thrombosis, especially thrombotic cerebrovascular disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: aspirin
      term:
        id: CHEBI:15365
        label: acetylsalicylic acid
    - preferred_term: warfarin
      term:
        id: CHEBI:10033
        label: warfarin
    - preferred_term: heparin
      term:
        id: CHEBI:28304
        label: heparin
  target_mechanisms:
  - target: Antiphospholipid-Associated Neurovascular Thrombosis
    treatment_effect: INHIBITS
    description: >-
      Antiplatelet and anticoagulant strategies reduce thrombus formation or
      recurrence in aPL-associated vascular NPSLE.
    evidence:
    - reference: PMID:20724309
      reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Antiplatelet/anticoagulation therapy is indicated when manifestations
        are related to antiphospholipid antibodies, particularly thrombotic CVD.
      explanation: >-
        EULAR directly links antithrombotic treatment to antiphospholipid
        antibody-associated thrombotic cerebrovascular NPSLE.
  target_phenotypes:
  - preferred_term: Ischemic stroke
    term:
      id: HP:0002140
      label: Ischemic stroke
  evidence:
  - reference: PMID:20724309
    reference_title: "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Antiplatelet/anticoagulation therapy is indicated when manifestations are
      related to antiphospholipid antibodies, particularly thrombotic CVD.
    explanation: >-
      EULAR supports antithrombotic therapy when NPSLE is aPL/thrombotic.
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      When symptoms are thought to reflect a thrombotic underlying process,
      anticoagulation and antiplatelet agents are the mainstay of therapy,
      especially if antiphospholipid antibodies or antiphospholipid syndrome are
      present.
    explanation: >-
      The management review supports mechanism-guided antithrombotic therapy.
- name: Steroid-Sparing Maintenance Immunosuppression
  description: >-
    Azathioprine or mycophenolate may be considered for mild to moderate
    inflammatory presentations or maintenance therapy after acute control,
    depending on the syndrome and overall SLE activity.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: azathioprine
      term:
        id: CHEBI:2948
        label: azathioprine
    - preferred_term: mycophenolate mofetil
      term:
        id: CHEBI:8764
        label: mycophenolate mofetil
  target_mechanisms:
  - target: Autoimmune Neuroinflammation
    treatment_effect: INHIBITS
    description: >-
      Steroid-sparing immunosuppressants reduce ongoing lymphocyte activation
      and immune-mediated inflammation.
    evidence:
    - reference: PMID:26809245
      reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        When patients present with mild to moderate NP manifestations, or when
        maintenance therapy is warranted, azathioprine and mycophenolate may be
        considered.
      explanation: >-
        The source supports maintenance or mild-to-moderate immunosuppression
        for inflammatory NPSLE contexts.
  evidence:
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      When patients present with mild to moderate NP manifestations, or when
      maintenance therapy is warranted, azathioprine and mycophenolate may be
      considered.
    explanation: >-
      The review supports azathioprine and mycophenolate for selected
      mild/moderate or maintenance contexts.
- name: Refractory NPSLE Escalation
  description: >-
    Rituximab, intravenous immunoglobulin, or plasmapheresis may be used in
    severe inflammatory NPSLE when response to initial glucocorticoid and
    cyclophosphamide-based treatment is inadequate.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
    - preferred_term: human immunoglobulin G
      term:
        id: NCIT:C80829
        label: Human Immunoglobulin G
  target_mechanisms:
  - target: Autoimmune Neuroinflammation
    treatment_effect: MODULATES
    description: >-
      B-cell depletion, immune modulation, and antibody removal can be used when
      severe antibody- or inflammation-mediated NPSLE is refractory.
    evidence:
    - reference: PMID:26809245
      reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Rituximab, intravenous immunoglobulins, or plasmapheresis may be used if
        response is not achieved.
      explanation: >-
        The source supports escalation to immune-targeted therapy when initial
        inflammatory NPSLE treatment response is inadequate.
  evidence:
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Rituximab, intravenous immunoglobulins, or plasmapheresis may be used if
      response is not achieved.
    explanation: >-
      The review supports rituximab, IVIG, or plasmapheresis as escalation
      options when response is inadequate.
  - reference: PMID:18537650
    reference_title: Therapeutic approach to neuropsychiatric systemic lupus erythematosus.
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      Intravenous immunoglobulins, mycophenolate mofetil, rituximab, intratecal
      methotrexate and dexametasone deserve further studies to confirm their
      usefulness in the treatment of neuropsychiatric SLE.
    explanation: >-
      This older review identifies IVIG, mycophenolate, and rituximab as
      plausible options while emphasizing limited evidence.
  - reference: PMID:42115580
    reference_title: "Long-term clinical outcomes and safety of rituximab in refractory neuropsychiatric systemic lupus erythematosus: a real-world single-center study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sixteen of 17 patients (94.1%) achieved significant clinical improvement,
      while one patient showed partial improvement with reduced seizure
      frequency.
    explanation: >-
      This refractory NPSLE cohort provides direct clinical support for
      rituximab as an escalation option, while infection risk still requires
      monitoring.
- name: Symptomatic Neuropsychiatric Management
  description: >-
    Syndrome-directed treatment such as antipsychotics, antiseizure therapy,
    antidepressants, and supportive neurologic or psychiatric care is used
    alongside mechanism-directed immunosuppression or antithrombotic therapy.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  - preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In the acute setting, management of these patients does not differ from
      other non-SLE subjects presenting with the same NP manifestation.
    explanation: >-
      This supports standard syndrome-directed acute care before and alongside
      lupus-specific attribution.
  - reference: PMID:30375754
    reference_title: "Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The following therapies were used during the time of the first psychotic
      events: corticosteroids in 23 of 28 patients (82.1%)
    explanation: >-
      The psychosis cohort documents combined immunosuppressive and symptomatic
      psychiatric treatments in real-world lupus psychosis.
progression:
- phase: Early lupus psychosis timing
  notes: >-
    Lupus psychosis tends to occur early around SLE diagnosis in the SLICC
    inception cohort, although it remains uncommon.
  evidence:
  - reference: PMID:30375754
    reference_title: "Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      there was a tendency for psychosis to occur early in the disease course,
      usually within the first 3 years following the diagnosis of SLE.
    explanation: >-
      The cohort supports early timing of SLE-attributed psychosis relative to
      SLE diagnosis.
- phase: Treatment-associated resolution of lupus psychosis
  notes: >-
    Most lupus psychosis events resolved or improved over follow-up in the SLICC
    cohort, supporting reversibility for many patients after recognition and
    treatment.
  evidence:
  - reference: PMID:30375754
    reference_title: "Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      More than 80% of the psychotic events had resolved by the second annual
      assessment following onset of the event
    explanation: >-
      This supports favorable resolution of most lupus psychosis events over
      two annual assessments.
- phase: Twelve-month treatment response after first NP event
  notes: >-
    In a 2024 international multicenter cohort of first neuropsychiatric events,
    SLE attribution by clinical judgment combined with immunosuppressant
    treatment was associated with better 12-month outcomes.
  evidence:
  - reference: DOI:10.1093/rheumatology/keae119
    reference_title: "Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicentre retrospective study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NP manifestations attributed to SLE by clinical judgment and treated with
      immunosuppressants demonstrated improved 12-month outcomes.
    explanation: >-
      This multicenter retrospective cohort supports timely attribution and
      immunosuppressive therapy for SLE-attributed NPSLE events.
- phase: Syndrome-dependent course and attribution uncertainty
  notes: >-
    NPSLE course and prognosis depend strongly on syndrome, mechanism, and
    attribution confidence; neuropsychiatric events may be inflammatory,
    thrombotic, mixed, or unrelated to SLE.
  evidence:
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A strict differential diagnosis and individualization of treatment,
      depending on the neuropsychiatric presentation and severity of symptoms,
      are crucial in neuropsychiatric systemic lupus erythematosus (NPSLE).
    explanation: >-
      This supports prognosis and management being syndrome- and
      mechanism-dependent rather than uniform across all NPSLE.
animal_models:
- species: Mouse
  genotype: MRL/lpr lupus-prone strain
  description: >-
    MRL/lpr mice are used as a lupus-prone model for CNS lupus mechanisms,
    including blood-brain barrier disruption, TWEAK/Fn14 signaling, complement
    pathway involvement, and cognitive or depression-like phenotypes.
  evidence:
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Studies in MRL/lpr mice, accurately reflecting human NPSLE, have shown the
      importance of TWEAK, a pro-inflammatory cytokine member of the TNF
      superfamily, and the alternative complement cascade in BBB disruption.
    explanation: >-
      The review supports MRL/lpr mice as a model for BBB and complement/cytokine
      mechanisms in NPSLE.
  - reference: PMID:26809245
    reference_title: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Furthermore, in a murine knockout model for its receptor Fn14, mice were
      found to improve in cognitive function and to have less depression and
      anhedonia
    explanation: >-
      The TWEAK receptor knockout observation supports model-system relevance to
      cognitive and mood-like NPSLE phenotypes.
datasets: []
references:
- reference: DOI:10.1007/s10875-022-01407-1
  title: "Juvenile Neuropsychiatric Systemic Lupus Erythematosus: Identification of Novel Central Neuroinflammation Biomarkers"
  found_in:
  - Neuropsychiatric_SLE-deep-research-falcon.md
  findings: []
- reference: DOI:10.1016/j.berh.2005.04.003
  title: Management of neuropsychiatric lupus
  found_in:
  - Neuropsychiatric_SLE-deep-research-falcon.md
  findings: []
- reference: DOI:10.1093/rheumatology/keae119
  title: "Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicentre retrospective study"
  found_in:
  - Neuropsychiatric_SLE-deep-research-falcon.md
  findings: []
- reference: DOI:10.1136/ard-2023-224762
  title: 'EULAR recommendations for the management of systemic lupus erythematosus: 2023 update'
  found_in:
  - Neuropsychiatric_SLE-deep-research-falcon.md
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: DOI:10.1177/09612033241272961
  title: Blood-based biomarkers of neuronal and glial injury in active major neuropsychiatric systemic lupus erythematosus
  found_in:
  - Neuropsychiatric_SLE-deep-research-falcon.md
  findings: []
- reference: DOI:10.3389/fneur.2023.1111769
  title: 'The conundrum of neuropsychiatric systemic lupus erythematosus: Current and novel approaches to diagnosis'
  found_in:
  - Neuropsychiatric_SLE-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/diagnostics14111186
  title: 'The Challenge of Neuropsychiatric Systemic Lupus Erythematosus: From Symptoms to Therapeutic Strategies'
  found_in:
  - Neuropsychiatric_SLE-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/molecules29040747
  title: 'Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment'
  found_in:
  - Neuropsychiatric_SLE-deep-research-falcon.md
  findings: []
- reference: DOI:10.7759/cureus.61678
  title: 'Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review'
  found_in:
  - Neuropsychiatric_SLE-deep-research-falcon.md
  findings: []
- reference: PMID:11327248
  title: Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:11971089
  title: 'Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:12491066
  title: '[Neuropsychiatric involvement in systemic lupus erythematosus. Part 1: clinical presentation and pathogenesis].'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:14975498
  title: The potential pathogenetic link between peripheral immune activation and the central innate immune response in neuropsychiatric systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:17875548
  title: 'Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:19565516
  title: Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:20800292
  title: Sex and autoantibody titers determine the development of neuropsychiatric manifestations in lupus-prone mice.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:21382916
  title: Hypomethylation of the HTR1A promoter region and high expression of HTR1A in the peripheral blood lymphocytes of patients with systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:22595642
  title: 'Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:23956915
  title: A patient with systemic lupus erythematosus complicated by neurological symptoms of toluene poisoning.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:25183233
  title: 'Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL-lpr mouse strain as a model.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:26524895
  title: '[Progress of Autoantibody Examinations for Connective Tissue Diseases].'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:27306639
  title: Systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:27889859
  title: Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:28030595
  title: 'Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:28134038
  title: Outcomes of 847 childhood-onset systemic lupus erythematosus patients in three age groups.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:28624334
  title: 'Seasonality and autoimmune diseases: The contribution of the four seasons to the mosaic of autoimmunity.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:29036223
  title: Evaluation of blood-brain barrier function by quotient alpha2 macroglobulin and its relationship with interleukin-6 and complement component 3 levels in neuropsychiatric systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:29846157
  title: Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:30657064
  title: Human immunodeficiency virus in a cohort of systemic lupus erythematosus patients.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:31022053
  title: 'Neuropsychiatric Syndromes in Childhood-Onset Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:32174913
  title: A Novel Microglia-Specific Transcriptional Signature Correlates With Behavioral Deficits in Neuropsychiatric Lupus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:32349105
  title: Advanced neuroimaging in neuropsychiatric systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:34495535
  title: Epigenetic Regulation of Glycosylation.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:34599046
  title: Schizophrenia Genetics and Neuropsychiatric Features in Childhood-onset Systemic Lupus Erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:34800169
  title: Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:35118639
  title: Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:35382378
  title: Association of <em>TNFAIP3</em> gene polymorphism (<em>rs5029939</em>) with susceptibility and clinical phenotype of systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:36081818
  title: Cognitive changes mediated by adenosine receptor blockade in a resveratrol-treated atherosclerosis-prone lupus mouse model.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:36465068
  title: 'Long-term Outcomes of Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study from CSTAR Registry.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:36494778
  title: Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:36852847
  title: Reduced homovanillic acid, SDF-1α and SCGF-β levels in cerebrospinal fluid are related to depressive states in systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:36898766
  title: Microglia activation in the presence of intact blood-brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:37369340
  title: Spatial enrichment of the type 1 interferon signature in the brain of a neuropsychiatric lupus murine model.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:37827694
  title: "EULAR recommendations for the management of systemic lupus erythematosus: 2023 update."
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:38531610
  title: Characterisation of choroid plexus-infiltrating T cells reveals novel therapeutic targets in murine neuropsychiatric lupus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:38997542
  title: 'Correlation between neuropsychiatric systemic lupus erythematosus and immunological markers: a real-world retrospective study.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:39299747
  title: 'Childhood-onset systemic lupus erythematosus in China, 2016-21: a nationwide study.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:39429812
  title: 'Neuropsychiatric prodromes and symptom timings in relation to disease onset and/or flares in SLE: results from the mixed methods international INSPIRE study.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:39904110
  title: IL-17A, IL-23R, FCGR3A are associated with neuropsychiatric systemic lupus erythematosus susceptibility in pediatric patients with lupus nephritis.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:40516332
  title: 'Lysine demethylase 6 (KDM6): A promising therapeutic target in autoimmune disorders and cancer.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:40818249
  title: 'Diffuse neuropsychiatric lupus: Clinical evidence, immune-mediated mechanisms, and therapeutic insights.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41039983
  title: Cytokine and IRF5 Gene Polymorphisms Associated With Susceptibility and Organ Damage in Systemic Lupus Erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41062154
  title: Unveiling the clinical and genetic impact of neuropsychiatric involvement in systemic lupus erythematosus.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41157255
  title: 'Vitamin D as an Immune Modulator in Systemic Lupus Erythematosus: A Narrative Review.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41307246
  title: 'Neuropsychiatric manifestations in systemic lupus erythematosus and antiphospholipid syndrome: pathophysiology and current insights.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41399085
  title: '[Central nervous system infection mimicking neuropsychiatric systemic lupus erythematosus: A case report].'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41608446
  title: 'Advancements in understanding neuropsychiatric lupus: deciphering immune heterogeneity with single-cell resolution.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41638970
  title: 'Leukodystrophy-like phenotype in early-onset neuropsychiatric systemic lupus erythematosus: Case series and systematic review of the literature.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41668759
  title: 'Clinical features and comorbidities of Epstein-Barr virus infection in childhood-onset systemic lupus erythematosus with a focus on macrophage activation syndrome: a cross-sectional study of 200 patients.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41739063
  title: 'Protective effect of antimalarials on the most frequently affected damage domains in SLE: Data from a multiethnic Latin American cohort.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41756273
  title: 'Rationale for investigating the use of anifrolumab in neuropsychiatric systemic lupus erythematosus: a combined narrative and case-based systematic literature review.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41795008
  title: 'Endothelial Dysfunction: Insights into Systemic Lupus Erythematosus-associated Cardiovascular Disease and Neuropsychiatric Manifestations.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41831216
  title: 'Unique brain mechanisms in early events in SLE with diffuse neuropsychiatric disease (NPSLE): Implications for the management.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41869319
  title: IFNγ-associated immune-metabolic remodeling is linked to serotonin-kynurenine imbalance and cortical vulnerability in lupus-prone mice.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41871917
  title: 'Frequency and associated factors of herpes zoster infection in SLE patients from Latin America: data from the GLADEL 2.0 cohort.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41969819
  title: 'Neuropsychiatric systemic lupus erythematosus subtypes identified by unsupervised clustering: A single-center cohort study.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:41989680
  title: Pathogenesis and therapeutic strategies for neuropsychiatric lupus centered on innate immune activation.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:42009372
  title: Adverse childhood experiences are associated with disease and mental health outcomes in childhood-onset SLE.
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:42115580
  title: 'Long-term clinical outcomes and safety of rituximab in refractory neuropsychiatric systemic lupus erythematosus: a real-world single-center study.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
- reference: PMID:42123548
  title: 'Genetic Polymorphisms in Systemic Lupus Erythematosus and Their Clinical Implications: A Narrative Review.'
  found_in:
  - Neuropsychiatric_SLE-deep-research-openscientist.md
  findings: []
📚

References & Deep Research

References

70
DOI:10.1007/s10875-022-01407-1
Juvenile Neuropsychiatric Systemic Lupus Erythematosus: Identification of Novel Central Neuroinflammation Biomarkers
No top-level findings curated for this source.
DOI:10.1016/j.berh.2005.04.003
Management of neuropsychiatric lupus
No top-level findings curated for this source.
DOI:10.1093/rheumatology/keae119
Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicentre retrospective study
No top-level findings curated for this source.
DOI:10.1136/ard-2023-224762
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
No top-level findings curated for this source.
DOI:10.1177/09612033241272961
Blood-based biomarkers of neuronal and glial injury in active major neuropsychiatric systemic lupus erythematosus
No top-level findings curated for this source.
DOI:10.3389/fneur.2023.1111769
The conundrum of neuropsychiatric systemic lupus erythematosus: Current and novel approaches to diagnosis
No top-level findings curated for this source.
DOI:10.3390/diagnostics14111186
The Challenge of Neuropsychiatric Systemic Lupus Erythematosus: From Symptoms to Therapeutic Strategies
No top-level findings curated for this source.
DOI:10.3390/molecules29040747
Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment
No top-level findings curated for this source.
DOI:10.7759/cureus.61678
Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review
No top-level findings curated for this source.
PMID:11327248
Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:11971089
Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.
No top-level findings curated for this source.
PMID:12491066
[Neuropsychiatric involvement in systemic lupus erythematosus. Part 1: clinical presentation and pathogenesis].
No top-level findings curated for this source.
PMID:14975498
The potential pathogenetic link between peripheral immune activation and the central innate immune response in neuropsychiatric systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:17875548
Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).
No top-level findings curated for this source.
PMID:19565516
Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:20800292
Sex and autoantibody titers determine the development of neuropsychiatric manifestations in lupus-prone mice.
No top-level findings curated for this source.
PMID:21382916
Hypomethylation of the HTR1A promoter region and high expression of HTR1A in the peripheral blood lymphocytes of patients with systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:22595642
Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort.
No top-level findings curated for this source.
PMID:23956915
A patient with systemic lupus erythematosus complicated by neurological symptoms of toluene poisoning.
No top-level findings curated for this source.
PMID:25183233
Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL-lpr mouse strain as a model.
No top-level findings curated for this source.
PMID:26524895
[Progress of Autoantibody Examinations for Connective Tissue Diseases].
No top-level findings curated for this source.
PMID:27306639
Systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:27889859
Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:28030595
Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort.
No top-level findings curated for this source.
PMID:28134038
Outcomes of 847 childhood-onset systemic lupus erythematosus patients in three age groups.
No top-level findings curated for this source.
PMID:28624334
Seasonality and autoimmune diseases: The contribution of the four seasons to the mosaic of autoimmunity.
No top-level findings curated for this source.
PMID:29036223
Evaluation of blood-brain barrier function by quotient alpha2 macroglobulin and its relationship with interleukin-6 and complement component 3 levels in neuropsychiatric systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:29846157
Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:30657064
Human immunodeficiency virus in a cohort of systemic lupus erythematosus patients.
No top-level findings curated for this source.
PMID:31022053
Neuropsychiatric Syndromes in Childhood-Onset Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis.
No top-level findings curated for this source.
PMID:32174913
A Novel Microglia-Specific Transcriptional Signature Correlates With Behavioral Deficits in Neuropsychiatric Lupus.
No top-level findings curated for this source.
PMID:32349105
Advanced neuroimaging in neuropsychiatric systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:34495535
Epigenetic Regulation of Glycosylation.
No top-level findings curated for this source.
PMID:34599046
Schizophrenia Genetics and Neuropsychiatric Features in Childhood-onset Systemic Lupus Erythematosus.
No top-level findings curated for this source.
PMID:34800169
Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:35118639
Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:35382378
Association of <em>TNFAIP3</em> gene polymorphism (<em>rs5029939</em>) with susceptibility and clinical phenotype of systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:36081818
Cognitive changes mediated by adenosine receptor blockade in a resveratrol-treated atherosclerosis-prone lupus mouse model.
No top-level findings curated for this source.
PMID:36465068
Long-term Outcomes of Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study from CSTAR Registry.
No top-level findings curated for this source.
PMID:36494778
Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus.
No top-level findings curated for this source.
PMID:36852847
Reduced homovanillic acid, SDF-1α and SCGF-β levels in cerebrospinal fluid are related to depressive states in systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:36898766
Microglia activation in the presence of intact blood-brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus.
No top-level findings curated for this source.
PMID:37369340
Spatial enrichment of the type 1 interferon signature in the brain of a neuropsychiatric lupus murine model.
No top-level findings curated for this source.
PMID:37827694
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
No top-level findings curated for this source.
PMID:38531610
Characterisation of choroid plexus-infiltrating T cells reveals novel therapeutic targets in murine neuropsychiatric lupus.
No top-level findings curated for this source.
PMID:38997542
Correlation between neuropsychiatric systemic lupus erythematosus and immunological markers: a real-world retrospective study.
No top-level findings curated for this source.
PMID:39299747
Childhood-onset systemic lupus erythematosus in China, 2016-21: a nationwide study.
No top-level findings curated for this source.
PMID:39429812
Neuropsychiatric prodromes and symptom timings in relation to disease onset and/or flares in SLE: results from the mixed methods international INSPIRE study.
No top-level findings curated for this source.
PMID:39904110
IL-17A, IL-23R, FCGR3A are associated with neuropsychiatric systemic lupus erythematosus susceptibility in pediatric patients with lupus nephritis.
No top-level findings curated for this source.
PMID:40516332
Lysine demethylase 6 (KDM6): A promising therapeutic target in autoimmune disorders and cancer.
No top-level findings curated for this source.
PMID:40818249
Diffuse neuropsychiatric lupus: Clinical evidence, immune-mediated mechanisms, and therapeutic insights.
No top-level findings curated for this source.
PMID:41039983
Cytokine and IRF5 Gene Polymorphisms Associated With Susceptibility and Organ Damage in Systemic Lupus Erythematosus.
No top-level findings curated for this source.
PMID:41062154
Unveiling the clinical and genetic impact of neuropsychiatric involvement in systemic lupus erythematosus.
No top-level findings curated for this source.
PMID:41157255
Vitamin D as an Immune Modulator in Systemic Lupus Erythematosus: A Narrative Review.
No top-level findings curated for this source.
PMID:41307246
Neuropsychiatric manifestations in systemic lupus erythematosus and antiphospholipid syndrome: pathophysiology and current insights.
No top-level findings curated for this source.
PMID:41399085
[Central nervous system infection mimicking neuropsychiatric systemic lupus erythematosus: A case report].
No top-level findings curated for this source.
PMID:41608446
Advancements in understanding neuropsychiatric lupus: deciphering immune heterogeneity with single-cell resolution.
No top-level findings curated for this source.
PMID:41638970
Leukodystrophy-like phenotype in early-onset neuropsychiatric systemic lupus erythematosus: Case series and systematic review of the literature.
No top-level findings curated for this source.
PMID:41668759
Clinical features and comorbidities of Epstein-Barr virus infection in childhood-onset systemic lupus erythematosus with a focus on macrophage activation syndrome: a cross-sectional study of 200 patients.
No top-level findings curated for this source.
PMID:41739063
Protective effect of antimalarials on the most frequently affected damage domains in SLE: Data from a multiethnic Latin American cohort.
No top-level findings curated for this source.
PMID:41756273
Rationale for investigating the use of anifrolumab in neuropsychiatric systemic lupus erythematosus: a combined narrative and case-based systematic literature review.
No top-level findings curated for this source.
PMID:41795008
Endothelial Dysfunction: Insights into Systemic Lupus Erythematosus-associated Cardiovascular Disease and Neuropsychiatric Manifestations.
No top-level findings curated for this source.
PMID:41831216
Unique brain mechanisms in early events in SLE with diffuse neuropsychiatric disease (NPSLE): Implications for the management.
No top-level findings curated for this source.
PMID:41869319
IFNγ-associated immune-metabolic remodeling is linked to serotonin-kynurenine imbalance and cortical vulnerability in lupus-prone mice.
No top-level findings curated for this source.
PMID:41871917
Frequency and associated factors of herpes zoster infection in SLE patients from Latin America: data from the GLADEL 2.0 cohort.
No top-level findings curated for this source.
PMID:41969819
Neuropsychiatric systemic lupus erythematosus subtypes identified by unsupervised clustering: A single-center cohort study.
No top-level findings curated for this source.
PMID:41989680
Pathogenesis and therapeutic strategies for neuropsychiatric lupus centered on innate immune activation.
No top-level findings curated for this source.
PMID:42009372
Adverse childhood experiences are associated with disease and mental health outcomes in childhood-onset SLE.
No top-level findings curated for this source.
PMID:42115580
Long-term clinical outcomes and safety of rituximab in refractory neuropsychiatric systemic lupus erythematosus: a real-world single-center study.
No top-level findings curated for this source.
PMID:42123548
Genetic Polymorphisms in Systemic Lupus Erythematosus and Their Clinical Implications: A Narrative Review.
No top-level findings curated for this source.

Deep Research

2
Falcon ▸
1. Disease Information
Edison Scientific Literature 32 citations 2026-05-16T12:04:52.093243

1. Disease Information

1.1 Overview / definition

NPSLE is commonly operationalized using the 1999 American College of Rheumatology (ACR) neuropsychiatric lupus nomenclature/case definitions, which defines 19 neuropsychiatric syndromes spanning central and peripheral nervous system involvement. (hanly2005managementofneuropsychiatric pages 1-3) Hanly & Harrison (2005), summarizing this framework, state that the ACR Research Committee produced “a standard nomenclature and diagnostic criteria for 19 NP syndromes” and that diagnosis is largely one of exclusion supported by imaging, electrophysiology, autoantibody profiles, and objective cognitive assessment. (hanly2005managementofneuropsychiatric pages 1-3)

1.2 Clinical classification frameworks

ACR 1999 neuropsychiatric syndromes (CNS/PNS) listed in Hanly & Harrison (2005): - CNS: aseptic meningitis; cerebrovascular disease; demyelinating syndrome; headache; movement disorder; myelopathy; seizure disorders; acute confusional state; anxiety disorder; cognitive dysfunction; mood disorder; psychosis. (hanly2005managementofneuropsychiatric pages 1-3) - PNS: Guillain–Barré syndrome; autonomic neuropathy; mononeuropathy; myasthenia gravis; cranial neuropathy; plexopathy; polyneuropathy. (hanly2005managementofneuropsychiatric pages 1-3)

1.3 Synonyms / alternative names

Historically, older terms such as “CNS lupus” and “lupus cerebritis” have been used (and are referenced as prior terminology in recent reviews), but contemporary literature generally uses “neuropsychiatric systemic lupus erythematosus (NPSLE)” and ACR syndrome-based descriptors. (justizvaillant2024neuropsychiatricsystemiclupus pages 1-2)

1.4 Key identifiers (ontology and coding)

  • MeSH terms observed in clinical trial registry records relevant to CNS lupus/NPSLE include “Lupus Vasculitis, Central Nervous System” (MeSH D020945) and “Lupus Erythematosus, Systemic” (MeSH D008180). (NCT07281105 chunk 2)
  • MONDO / Orphanet / ICD-10/ICD-11 codes: not identified in the retrieved full-text evidence in this run; therefore not asserted here.

1.5 Evidence source type

This report is derived from aggregated disease-level resources (reviews, systematic reviews, guidelines) and human clinical observational studies, plus registered clinical trials; it is not derived from individual EHR records. (bortoluzzi2024therapeuticstrategiesand pages 1-6, kammeyer2024bloodbasedbiomarkersof pages 1-3, emerson2023theconundrumof pages 1-2, NCT07281105 chunk 1)

2. Etiology

2.1 Disease causal factors (mechanistic)

Current evidence supports multifactorial causation, with overlapping inflammatory/autoimmune and vascular pathways. Hanly & Harrison (2005) highlight candidate primary mechanisms including “intracranial microangiopathy, autoantibodies to neuronal and non-neuronal antigens, and the generation of proinflammatory cytokines and mediators.” (hanly2005managementofneuropsychiatric pages 1-3) A 2024 review similarly emphasizes that NPSLE pathogenesis is “thought to involve inflammatory and vascular pathways,” reinforcing the dual-mechanism view used clinically to guide therapy. (patel2024thechallengeof pages 11-13)

2.2 Risk factors (human clinical)

Risk factors summarized in the 2024 Diagnostics review include: - Generalized SLE disease activity as a risk factor for NP manifestations, and NPSLE is “often seen in 40–50% of patients with generalized SLE activity” (as reported in that review). (patel2024thechallengeof pages 4-5) - Antiphospholipid antibodies (aPL) as a risk factor, especially for cerebrovascular disease and other vascular manifestations. (patel2024thechallengeof pages 4-5) - Additional associations for specific syndromes (e.g., psychosis) described in that review include male sex, younger age at SLE diagnosis, and ancestry-related differences, though these are summarized from prior literature rather than established as diagnostic. (patel2024thechallengeof pages 4-5)

2.3 Protective factors / gene–environment interactions

Protective factors and explicit gene–environment interactions specific to NPSLE were not directly quantified in the retrieved evidence corpus; therefore no claims are made here.

3. Phenotypes (clinical manifestations)

3.1 Phenotype spectrum and frequency

Reported frequency varies widely because syndrome definitions and attribution stringency differ. - Emerson et al. (2023) state: “The prevalence rates of NPSLE vary widely in the published literature, estimated to be between 12 and 95%.” (emerson2023theconundrumof pages 1-2) - Hanly & Harrison (2005) summarize prevalence across cohorts using ACR nomenclature: overall NP prevalence 37–95%, with common manifestations including cognitive dysfunction 55–80%, headache 24–72%, mood disorder 14–57%, cerebrovascular disease 5–18%, seizures 6–51%, polyneuropathy 3–28%, anxiety 7–24%, psychosis 0–8%. (hanly2005managementofneuropsychiatric pages 1-3) - A 2024 systematic review reported syndrome-specific prevalence estimates including status epilepticus and transverse myelitis around 1–2%, while cognitive dysfunction approached ~38% across included studies. (ricecanetto2024neuropsychiatricsystemiclupus pages 1-2)

3.2 Pediatric phenotype and timing

In juvenile SLE, Labouret et al. reported among 51 patients with juvenile SLE, 39% had juvenile NPSLE, and NPSLE occurred at SLE onset in 65%. (labouret2023juvenileneuropsychiatricsystemic pages 1-2)

3.3 Quality of life impacts

NPSLE is associated with substantial morbidity and reduced quality of life. Kammeyer et al. note that NPSLE is associated with “decreased quality of life and a significant increase in morbidity, mortality, hospitalization, and disease related costs compared to SLE without NP symptoms.” (kammeyer2024bloodbasedbiomarkersof pages 1-3)

3.4 Suggested HPO terms (examples for knowledge-base mapping)

Below are recommended HPO mappings for common ACR syndromes (term names only; IDs should be validated in downstream curation): - Cognitive dysfunction → Cognitive impairment (HP: Cognitive impairment) - Seizure disorder/status epilepticus → Seizures (HP: Seizures) - Psychosis → Psychosis (HP: Psychosis) - Mood disorder/depression → Depressed mood (HP: Depressed mood) - Headache → Headache (HP: Headache) - Cerebrovascular disease/stroke → Stroke (HP: Stroke) - Myelopathy/transverse myelitis → Myelopathy (HP: Myelopathy) - Polyneuropathy → Peripheral neuropathy (HP: Peripheral neuropathy) These phenotype selections are consistent with the ACR syndrome list and the clinical emphasis in reviews. (hanly2005managementofneuropsychiatric pages 1-3)

4. Genetic / Molecular Information

4.1 Genetic susceptibility (limited in retrieved corpus)

A 2024 review highlights genetic contributors to SLE/NPSLE broadly, referencing defective apoptosis (e.g., FAS) and REL/NF-κB pathway associations, but without NPSLE-specific causal variants established in the retrieved text. (justizvaillant2024neuropsychiatricsystemiclupus pages 1-2)

4.2 Key molecular mediators and autoantibodies

Inflammatory mediators and autoantibodies repeatedly implicated include: - Cytokines such as IL-6 and type I interferon (IFN-α) (with CSF IFN-α emerging in pediatric NPSLE biomarker work). (labouret2023juvenileneuropsychiatricsystemic pages 1-2, patel2024thechallengeof pages 4-5) - Broad autoimmune effectors (immune complexes, circulating antibodies, cytokines, autoreactive T cells) highlighted as drivers of tissue injury in NPSLE-focused reviews. (justizvaillant2024neuropsychiatricsystemiclupus pages 1-2)

4.3 Suggested GO terms (biological process) and CL terms (cell types)

Mechanistically motivated ontology suggestions based on the reviewed evidence include: - GO biological process: type I interferon signaling pathway, complement activation, inflammatory response, blood–brain barrier maintenance/disruption. (labouret2023juvenileneuropsychiatricsystemic pages 1-2) - Cell types (CL): microglial cell, astrocyte, brain endothelial cell (relevant to CSF neopterin concept and BBB-focused mechanisms). (labouret2023juvenileneuropsychiatricsystemic pages 1-2)

5. Mechanism / Pathophysiology (causal chains)

5.1 Two major mechanistic clusters used clinically: inflammatory vs vascular/ischemic

Clinical practice commonly separates NPSLE into processes dominated by inflammation versus thrombotic/ischemic injury to guide therapy. (bortoluzzi2024therapeuticstrategiesand pages 9-11) Bortoluzzi et al. explicitly note that “Current recommendations advocate for a therapeutic approach aimed at targeting the underlying pathophysiological mechanisms in NPSLE differentiating inflammatory or embolic/thrombotic/ischemic process,” with glucocorticoids/immunosuppressants used for inflammation and anticoagulant/antithrombotic interventions favored when aPL antibodies point toward vascular mechanisms. (bortoluzzi2024therapeuticstrategiesand pages 9-11)

5.2 Neuroinflammation and intrathecal type I interferon

In juvenile NPSLE, Labouret et al. found no specific routine biological or radiological marker, but observed that CSF neopterin was significantly higher in active CNS-involved NPSLE (p=0.0008) and that CSF IFN-α and neopterin decreased after clinical resolution under immunosuppressive treatment (p=0.0010–0.0015), supporting a model of CNS immune activation / interferon-associated neuroinflammation. (labouret2023juvenileneuropsychiatricsystemic pages 1-2)

5.3 Neuronal and glial injury as a final common pathway (2024 biomarker advance)

Kammeyer et al. (2024) evaluated blood-based neurofilament light (NfL) and GFAP as accessible indicators of neuronal/glial injury in active major NPSLE and observed substantially higher levels in active NPSLE than disease-matched SLE controls, with decreases after immunotherapy in a subset. (kammeyer2024bloodbasedbiomarkersof pages 1-3) This supports a causal chain: upstream immune/vascular injury → axonal/glial damage → elevated NfL/GFAP detectable peripherally, potentially enabling monitoring and earlier recognition. (kammeyer2024bloodbasedbiomarkersof pages 1-3)

6. Diagnostics (and differential diagnosis)

6.1 Diagnostic concept: attribution and exclusion

Hanly & Harrison (2005) emphasize that “The diagnosis of NP-SLE remains largely one of exclusion,” requiring evaluation for non-SLE causes (therapy complications, comorbidities) before attribution to lupus mechanisms. (hanly2005managementofneuropsychiatric pages 1-3) Emerson et al. (2023) similarly highlight barriers including “the heterogeneity of neurological symptoms, the absence of standardized assessment, [and] the unreliability of conventional markers,” motivating use of composite panels. (emerson2023theconundrumof pages 1-2)

6.2 Conventional investigations (real-world implementation)

A 2024 review outlines that workup is tailored to the presenting syndrome and begins with excluding secondary causes (infection, metabolic/endocrine disorders, adverse drug reactions, malignancy) and then incorporates labs, autoantibody assessments including aPL testing, imaging, and CSF studies as indicated, often requiring multidisciplinary care (neurology/psychiatry/neuroradiology). (patel2024thechallengeof pages 4-5)

6.3 Emerging/novel biomarkers (2023–2024)

  • CSF IFN-α and neopterin (pediatric): elevated in active CNS-involved j-NPSLE and decrease after treatment, with strong correlation (Rs=0.832). (labouret2023juvenileneuropsychiatricsystemic pages 1-2)
  • Blood NfL and GFAP (adult/teen major NPSLE): active major NPSLE vs SLE controls showed NfL +17.9 pg/mL and GFAP +3.2 pg/mL (both p<0.001); blood and CSF levels correlated (r=0.81–0.88). (kammeyer2024bloodbasedbiomarkersof pages 1-3, kammeyer2024bloodbasedbiomarkersof pages 5-6)

6.4 Suggested LOINC-style lab concepts (non-exhaustive)

  • CSF interferon-alpha protein; CSF neopterin; plasma/serum neurofilament light; plasma/serum GFAP; serum complements (C3/C4); anti-dsDNA titers; antiphospholipid antibody panel. These are supported by biomarker-focused primary studies and diagnostic review content. (kammeyer2024bloodbasedbiomarkersof pages 1-3, labouret2023juvenileneuropsychiatricsystemic pages 1-2, patel2024thechallengeof pages 4-5)

7. Outcomes / Prognosis

7.1 Real-world outcomes (2024 multicenter cohort)

In an international multicenter retrospective study of first NP events (350 events), 64% improved at 12 months; focal central events improved frequently (83% for focal central events in the excerpted results), and SLE-attributed events improved more often. (bortoluzzi2024therapeuticstrategiesand pages 9-11, bortoluzzi2024therapeuticstrategiesand pages 1-6) Importantly, patients whose NP manifestation was attributed to SLE by clinical judgment and treated with immunosuppressants had a higher probability of response (OR 2.55, 95% CI 1.06–6.41). (bortoluzzi2024therapeuticstrategiesand pages 1-6)

7.2 Syndrome-dependent prognosis (systematic review)

A 2024 systematic review reported prognosis as highly syndrome-dependent, including a 12.5% one-year mortality in status epilepticus/seizure presentations, while some other presentations may resolve. (ricecanetto2024neuropsychiatricsystemiclupus pages 1-2)

7.3 Prognostic/monitoring biomarkers

Kammeyer et al. observed that in a subset with longitudinal sampling, blood NfL and GFAP “decreased after immunotherapy,” suggesting potential utility for monitoring treatment response, though larger longitudinal validation is needed. (kammeyer2024bloodbasedbiomarkersof pages 1-3)

8. Treatment (guidelines, real-world implementation, and trials)

8.1 Guideline-level management principles relevant to NPSLE

The EULAR 2023 update (published 2024) provides overarching SLE treatment principles relevant to NPSLE management (universal HCQ, steroid minimization, early steroid-sparing therapy). (fanouriakis2024eularrecommendationsfor pages 10-11) Fanouriakis et al. recommend hydroxychloroquine for all patients at a target dose 5 mg/kg/day, and minimizing maintenance glucocorticoids to ≤5 mg/day prednisone equivalent with withdrawal when possible. (fanouriakis2024eularrecommendationsfor pages 10-11) For organ-threatening/refractory disease, the guideline notes roles for cyclophosphamide and rituximab, respectively. (fanouriakis2024eularrecommendationsfor pages 10-11)

8.2 Specific point for severe neuropsychiatric disease (EULAR figure)

The EULAR treatment framework figure explicitly states: “For patients with severe neuropsychiatric disease, anifrolumab and belimumab are not recommended.” (fanouriakis2024eularrecommendationsfor media 9daa74df)

8.3 Syndrome- and mechanism-guided therapy (inflammatory vs ischemic)

A contemporary approach described in the multicenter cohort discussion is to align therapy with inferred mechanism: glucocorticoids/immunosuppressants for inflammatory NPSLE; antithrombotic/anticoagulant approaches when aPL-associated vascular mechanisms predominate. (bortoluzzi2024therapeuticstrategiesand pages 9-11) A 2024 review’s proposed algorithm similarly includes immunosuppressive escalation (glucocorticoids, cyclophosphamide, azathioprine, mycophenolate) and rescue options (IVIg, plasmapheresis, rituximab) for refractory inflammatory disease, plus antithrombotic therapy for thrombotic/ischemic manifestations. (patel2024thechallengeof pages 10-11)

8.4 Real-world implementation and outcomes (2024 multicenter cohort)

Bortoluzzi et al. observed that immunosuppressants and corticosteroids were initiated/escalated more frequently in central diffuse or focal NP events attributed to SLE, and that this strategy was associated with improved outcomes at 12 months in clinically judged SLE-attributed events. (bortoluzzi2024therapeuticstrategiesand pages 9-11, bortoluzzi2024therapeuticstrategiesand pages 1-6)

8.5 Experimental/clinical trials (selected; real-world pipeline)

  • EG-501 (low-affinity NMDA receptor antagonist) for cognitive impairment in NPSLE (Phase 2, randomized placebo-controlled): registry record shows the trial was COMPLETED, with primary completion 2025-08-12, and describes NPSLE cognitive impairment as a serious unmet need; the primary endpoint used RBANS Total Index Score. (NCT07281105 chunk 1)
  • INLES (NCT05880121) observational connectomics + immune correlates: integrates advanced MRI with identification of candidate autoantigens/immune fingerprints for NPSLE. (NCT05880121 chunk 1)
  • fMRI early brain injury study (NCT06226324): posted 2024-01-26, prospective case-control design to detect early brain functional changes in SLE ± neuropsychiatric symptoms. (NCT06226324 chunk 1)

8.6 Suggested MAXO terms (examples)

  • Immunosuppressive therapy → Immunosuppressive therapy (MAXO) (e.g., glucocorticoid therapy, cyclophosphamide therapy, mycophenolate therapy). (patel2024thechallengeof pages 10-11)
  • Antithrombotic therapy → Anticoagulant therapy / antiplatelet therapy (MAXO) for aPL-associated ischemic NPSLE. (bortoluzzi2024therapeuticstrategiesand pages 9-11)
  • Neuropsychiatric symptomatic treatment → Antiepileptic therapy, antipsychotic therapy, antidepressant therapy, anxiolytic therapy (MAXO mappings). (patel2024thechallengeof pages 10-11)

9. Prevention

Primary prevention specific to NPSLE (i.e., preventing first neuropsychiatric event) is not established in the retrieved evidence corpus. However, tertiary prevention principles are implicit in guideline approaches to reduce flares and steroid exposure in SLE generally and in mechanism-guided management of NP events (minimize glucocorticoid toxicity; treat active disease promptly; address thrombosis risk when aPL present). (fanouriakis2024eularrecommendationsfor pages 10-11, bortoluzzi2024therapeuticstrategiesand pages 9-11)

10. Other species / natural disease

Not addressed in the retrieved evidence corpus.

11. Model organisms / experimental systems

A 2024 review reports preclinical evidence that ACE inhibitors reduced type I interferon responses and improved cognitive deficits in mice, suggesting a neuroimmune-interferon axis that might be therapeutically targetable, though this remains preclinical. (patel2024thechallengeof pages 11-13)

12. Recent developments & expert analysis (2023–2024)

12.1 Diagnostic paradigm shift: composite panels and endophenotypes

Emerson et al. (2023) advocate moving beyond NPSLE as a single entity and emphasize that “a composite panel of these investigations will be needed” due to non-specificity of individual tests. (emerson2023theconundrumof pages 1-2) This is consistent with 2023–2024 biomarker advances (CSF IFN-α/neopterin; blood NfL/GFAP) that are not individually definitive but provide quantifiable signals of CNS immune activation and neural injury. (kammeyer2024bloodbasedbiomarkersof pages 1-3, labouret2023juvenileneuropsychiatricsystemic pages 1-2)

12.2 Practical treatment insight from multicenter real-world data

The 2024 multicenter cohort provides actionable evidence that attribution (clinical judgment) combined with immunosuppressive treatment is associated with better 12-month outcomes, quantifying benefit (OR 2.55). (bortoluzzi2024therapeuticstrategiesand pages 1-6)

13. Abstract-supported direct quotes (for knowledge-base evidence items)

  • Emerson et al. (2023) abstract: “The prevalence rates of NPSLE vary widely in the published literature, estimated to be between 12 and 95%.” (emerson2023theconundrumof pages 1-2)
  • Emerson et al. (2023) abstract: “Novel serum and CSF markers, including autoantibodies, cytokines and chemokines have also shown increasing utility …” (emerson2023theconundrumof pages 1-2)
  • Kammeyer et al. (2024) abstract: “Blood NfL was on average 17.9 pg/ml higher … and blood GFAP was on average 3.2 pg/ml higher … for cases of active major NPSLE compared to SLE without active major NPSLE.” (kammeyer2024bloodbasedbiomarkersof pages 1-3)
  • Labouret et al. (2023) abstract: “CSF IFN-α and neopterin constitute promising biomarkers useful in the diagnosis and monitoring of activity in j-NPSLE.” (labouret2023juvenileneuropsychiatricsystemic pages 1-2)

14. Key gaps and limitations of this tool-based synthesis

  • Several requested standardized identifiers (MONDO, Orphanet, ICD-10/ICD-11) were not present in the retrieved evidence corpus; they should be added via dedicated ontology lookups outside this run.
  • Gene/variant-level evidence specific to NPSLE susceptibility was limited in the retrieved full texts; additional GWAS/ClinVar/ClinGen and NPSLE-focused genomics studies would strengthen Sections 2 and 4.

References (URLs and publication dates are embedded above where available)

Key 2023–2024 sources emphasized include Emerson et al. 2023 (Frontiers in Neurology), Labouret et al. 2023 (J Clin Immunol), Fanouriakis et al. 2024 (Ann Rheum Dis; EULAR 2023 update), Bortoluzzi et al. 2024 (Rheumatology), Kammeyer et al. 2024 (Lupus), and Rice-Canetto et al. 2024 (Cureus). (bortoluzzi2024therapeuticstrategiesand pages 1-6, kammeyer2024bloodbasedbiomarkersof pages 1-3, labouret2023juvenileneuropsychiatricsystemic pages 1-2, emerson2023theconundrumof pages 1-2, fanouriakis2024eularrecommendationsfor media 9daa74df)

References

  1. (hanly2005managementofneuropsychiatric pages 1-3): John G. Hanly and Melanie J. Harrison. Management of neuropsychiatric lupus. Best practice & research. Clinical rheumatology, 19 5:799-821, Oct 2005. URL: https://doi.org/10.1016/j.berh.2005.04.003, doi:10.1016/j.berh.2005.04.003. This article has 126 citations.

  2. (patel2024thechallengeof pages 4-5): Veena Patel. The challenge of neuropsychiatric systemic lupus erythematosus: from symptoms to therapeutic strategies. Diagnostics, 14:1186, Jun 2024. URL: https://doi.org/10.3390/diagnostics14111186, doi:10.3390/diagnostics14111186. This article has 27 citations.

  3. (kammeyer2024bloodbasedbiomarkersof pages 1-3): Ryan Kammeyer, Kimberly Chapman, Anna Furniss, Elena Hsieh, Robert Fuhlbrigge, Ekemini A. Ogbu, Susan Boackle, JoAnn Zell, Kavita V. Nair, Tyler L. Borko, Jennifer C. Cooper, Jeffrey L. Bennett, and Amanda L. Piquet. Blood-based biomarkers of neuronal and glial injury in active major neuropsychiatric systemic lupus erythematosus. Lupus, 33:1116-1129, Aug 2024. URL: https://doi.org/10.1177/09612033241272961, doi:10.1177/09612033241272961. This article has 15 citations and is from a peer-reviewed journal.

  4. (labouret2023juvenileneuropsychiatricsystemic pages 1-2): Mathilde Labouret, Stefania Costi, Vincent Bondet, Vincent Trebossen, Enora Le Roux, Alexandra Ntorkou, Sophie Bartoli, Stéphane Auvin, Brigitte Bader-Meunier, Véronique Baudouin, Olivier Corseri, Glory Dingulu, Camille Ducrocq, Cécile Dumaine, Monique Elmaleh, Nicole Fabien, Albert Faye, Isabelle Hau, Véronique Hentgen, Théresa Kwon, Ulrich Meinzer, Naim Ouldali, Cyrielle Parmentier, Marie Pouletty, Florence Renaldo, Isabelle Savioz, Flore Rozenberg, Marie-Louise Frémond, Alice Lepelley, Gillian I. Rice, Luis Seabra, Jean-François Benoist, Darragh Duffy, Yanick J. Crow, Pierre Ellul, and Isabelle Melki. Juvenile neuropsychiatric systemic lupus erythematosus: identification of novel central neuroinflammation biomarkers. Journal of Clinical Immunology, 43:615-624, Dec 2023. URL: https://doi.org/10.1007/s10875-022-01407-1, doi:10.1007/s10875-022-01407-1. This article has 28 citations and is from a domain leading peer-reviewed journal.

  5. (emerson2023theconundrumof pages 1-2): Jonathan S. Emerson, Simon M. Gruenewald, Lavier Gomes, Ming-Wei Lin, and Sanjay Swaminathan. The conundrum of neuropsychiatric systemic lupus erythematosus: current and novel approaches to diagnosis. Frontiers in Neurology, Mar 2023. URL: https://doi.org/10.3389/fneur.2023.1111769, doi:10.3389/fneur.2023.1111769. This article has 53 citations and is from a peer-reviewed journal.

  6. (ricecanetto2024neuropsychiatricsystemiclupus pages 1-2): Tyler E Rice-Canetto, Sonali J Joshi, Katie A Kyan, and Javed Siddiqi. Neuropsychiatric systemic lupus erythematosus: a systematic review. Cureus, Jun 2024. URL: https://doi.org/10.7759/cureus.61678, doi:10.7759/cureus.61678. This article has 13 citations.

  7. (kammeyer2024bloodbasedbiomarkersof pages 5-6): Ryan Kammeyer, Kimberly Chapman, Anna Furniss, Elena Hsieh, Robert Fuhlbrigge, Ekemini A. Ogbu, Susan Boackle, JoAnn Zell, Kavita V. Nair, Tyler L. Borko, Jennifer C. Cooper, Jeffrey L. Bennett, and Amanda L. Piquet. Blood-based biomarkers of neuronal and glial injury in active major neuropsychiatric systemic lupus erythematosus. Lupus, 33:1116-1129, Aug 2024. URL: https://doi.org/10.1177/09612033241272961, doi:10.1177/09612033241272961. This article has 15 citations and is from a peer-reviewed journal.

  8. (labouret2023juvenileneuropsychiatricsystemic pages 4-5): Mathilde Labouret, Stefania Costi, Vincent Bondet, Vincent Trebossen, Enora Le Roux, Alexandra Ntorkou, Sophie Bartoli, Stéphane Auvin, Brigitte Bader-Meunier, Véronique Baudouin, Olivier Corseri, Glory Dingulu, Camille Ducrocq, Cécile Dumaine, Monique Elmaleh, Nicole Fabien, Albert Faye, Isabelle Hau, Véronique Hentgen, Théresa Kwon, Ulrich Meinzer, Naim Ouldali, Cyrielle Parmentier, Marie Pouletty, Florence Renaldo, Isabelle Savioz, Flore Rozenberg, Marie-Louise Frémond, Alice Lepelley, Gillian I. Rice, Luis Seabra, Jean-François Benoist, Darragh Duffy, Yanick J. Crow, Pierre Ellul, and Isabelle Melki. Juvenile neuropsychiatric systemic lupus erythematosus: identification of novel central neuroinflammation biomarkers. Journal of Clinical Immunology, 43:615-624, Dec 2023. URL: https://doi.org/10.1007/s10875-022-01407-1, doi:10.1007/s10875-022-01407-1. This article has 28 citations and is from a domain leading peer-reviewed journal.

  9. (bortoluzzi2024therapeuticstrategiesand pages 9-11): Alessandra Bortoluzzi, Antonis Fanouriakis, Ettore Silvagni, Simone Appenzeller, Linda Carli, Greta Carrara, Alberto Cauli, Fabrizio Conti, Lilian Teresa Lavras Costallat, Ginevra De Marchi, Andrea Doria, Micaela Fredi, Franco Franceschini, Carlo Garaffoni, John G Hanly, Marta Mosca, Elana Murphy, Matteo Piga, Luca Quartuccio, Carlo Alberto Scirè, Paola Tomietto, Simona Truglia, Anna Zanetti, Margherita Zen, George Bertsias, and Marcello Govoni. Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicenter retrospective study. Rheumatology, 63:2711-2720, Feb 2024. URL: https://doi.org/10.1093/rheumatology/keae119, doi:10.1093/rheumatology/keae119. This article has 14 citations and is from a peer-reviewed journal.

  10. (bortoluzzi2024therapeuticstrategiesand pages 1-6): Alessandra Bortoluzzi, Antonis Fanouriakis, Ettore Silvagni, Simone Appenzeller, Linda Carli, Greta Carrara, Alberto Cauli, Fabrizio Conti, Lilian Teresa Lavras Costallat, Ginevra De Marchi, Andrea Doria, Micaela Fredi, Franco Franceschini, Carlo Garaffoni, John G Hanly, Marta Mosca, Elana Murphy, Matteo Piga, Luca Quartuccio, Carlo Alberto Scirè, Paola Tomietto, Simona Truglia, Anna Zanetti, Margherita Zen, George Bertsias, and Marcello Govoni. Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicenter retrospective study. Rheumatology, 63:2711-2720, Feb 2024. URL: https://doi.org/10.1093/rheumatology/keae119, doi:10.1093/rheumatology/keae119. This article has 14 citations and is from a peer-reviewed journal.

  11. (fanouriakis2024eularrecommendationsfor pages 10-11): Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, Martin Aringer, Laurent Arnaud, Sang-Cheol Bae, John Boletis, Ian N Bruce, Ricard Cervera, Andrea Doria, Thomas Dörner, Richard A Furie, Dafna D Gladman, Frederic A Houssiau, Luís Sousa Inês, David Jayne, Marios Kouloumas, László Kovács, Chi Chiu Mok, Eric F Morand, Gabriella Moroni, Marta Mosca, Johanna Mucke, Chetan B Mukhtyar, György Nagy, Sandra Navarra, Ioannis Parodis, José M Pego-Reigosa, Michelle Petri, Bernardo A Pons-Estel, Matthias Schneider, Josef S Smolen, Elisabet Svenungsson, Yoshiya Tanaka, Maria G Tektonidou, YK Onno Teng, Angela Tincani, Edward M Vital, Ronald F van Vollenhoven, Chris Wincup, George Bertsias, and Dimitrios T Boumpas. Eular recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases, 83:15-29, Jan 2024. URL: https://doi.org/10.1136/ard-2023-224762, doi:10.1136/ard-2023-224762. This article has 1255 citations and is from a highest quality peer-reviewed journal.

  12. (fanouriakis2024eularrecommendationsfor pages 7-8): Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, Martin Aringer, Laurent Arnaud, Sang-Cheol Bae, John Boletis, Ian N Bruce, Ricard Cervera, Andrea Doria, Thomas Dörner, Richard A Furie, Dafna D Gladman, Frederic A Houssiau, Luís Sousa Inês, David Jayne, Marios Kouloumas, László Kovács, Chi Chiu Mok, Eric F Morand, Gabriella Moroni, Marta Mosca, Johanna Mucke, Chetan B Mukhtyar, György Nagy, Sandra Navarra, Ioannis Parodis, José M Pego-Reigosa, Michelle Petri, Bernardo A Pons-Estel, Matthias Schneider, Josef S Smolen, Elisabet Svenungsson, Yoshiya Tanaka, Maria G Tektonidou, YK Onno Teng, Angela Tincani, Edward M Vital, Ronald F van Vollenhoven, Chris Wincup, George Bertsias, and Dimitrios T Boumpas. Eular recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases, 83:15-29, Jan 2024. URL: https://doi.org/10.1136/ard-2023-224762, doi:10.1136/ard-2023-224762. This article has 1255 citations and is from a highest quality peer-reviewed journal.

  13. (fanouriakis2024eularrecommendationsfor media 9daa74df): Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, Martin Aringer, Laurent Arnaud, Sang-Cheol Bae, John Boletis, Ian N Bruce, Ricard Cervera, Andrea Doria, Thomas Dörner, Richard A Furie, Dafna D Gladman, Frederic A Houssiau, Luís Sousa Inês, David Jayne, Marios Kouloumas, László Kovács, Chi Chiu Mok, Eric F Morand, Gabriella Moroni, Marta Mosca, Johanna Mucke, Chetan B Mukhtyar, György Nagy, Sandra Navarra, Ioannis Parodis, José M Pego-Reigosa, Michelle Petri, Bernardo A Pons-Estel, Matthias Schneider, Josef S Smolen, Elisabet Svenungsson, Yoshiya Tanaka, Maria G Tektonidou, YK Onno Teng, Angela Tincani, Edward M Vital, Ronald F van Vollenhoven, Chris Wincup, George Bertsias, and Dimitrios T Boumpas. Eular recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases, 83:15-29, Jan 2024. URL: https://doi.org/10.1136/ard-2023-224762, doi:10.1136/ard-2023-224762. This article has 1255 citations and is from a highest quality peer-reviewed journal.

  14. (justizvaillant2024neuropsychiatricsystemiclupus pages 1-2): Angel A. Justiz-Vaillant, Darren Gopaul, Sachin Soodeen, Rodolfo Arozarena-Fundora, Odette Arozarena Barbosa, Chandrashehkar Unakal, Reinand Thompson, Bijay Pandit, Srikanth Umakanthan, and Patrick E. Akpaka. Neuropsychiatric systemic lupus erythematosus: molecules involved in its imunopathogenesis, clinical features, and treatment. Molecules, 29:747, Feb 2024. URL: https://doi.org/10.3390/molecules29040747, doi:10.3390/molecules29040747. This article has 76 citations.

  15. (NCT07281105 chunk 2): EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study. Evergreen Therapeutics, Inc.. 2018. ClinicalTrials.gov Identifier: NCT07281105

  16. (NCT07281105 chunk 1): EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study. Evergreen Therapeutics, Inc.. 2018. ClinicalTrials.gov Identifier: NCT07281105

  17. (patel2024thechallengeof pages 11-13): Veena Patel. The challenge of neuropsychiatric systemic lupus erythematosus: from symptoms to therapeutic strategies. Diagnostics, 14:1186, Jun 2024. URL: https://doi.org/10.3390/diagnostics14111186, doi:10.3390/diagnostics14111186. This article has 27 citations.

  18. (patel2024thechallengeof pages 10-11): Veena Patel. The challenge of neuropsychiatric systemic lupus erythematosus: from symptoms to therapeutic strategies. Diagnostics, 14:1186, Jun 2024. URL: https://doi.org/10.3390/diagnostics14111186, doi:10.3390/diagnostics14111186. This article has 27 citations.

  19. (NCT05880121 chunk 1): Giuseppe A. Ramirez. Neuron-specific Humoral and Cellular Immune Correlates of Structural and Functional Brain Connectomics in Neuropsychiatric Lupus. IRCCS San Raffaele. 2023. ClinicalTrials.gov Identifier: NCT05880121

  20. (NCT06226324 chunk 1): fMRI Study of Early Brain Injury in Systemic Lupus Erythematosus. The Affiliated Hospital of Inner Mongolia Medical University. 2023. ClinicalTrials.gov Identifier: NCT06226324

Artifacts

OpenScientist ▸
Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Comprehensive Disease Characterization Report
openscientist-autonomous 65 citations 2026-05-16T12:22:25.227611

Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Comprehensive Disease Characterization Report

Summary

Neuropsychiatric Systemic Lupus Erythematosus (NPSLE) is a severe, heterogeneous manifestation of systemic lupus erythematosus (SLE) in which autoimmune-mediated processes target the central and peripheral nervous systems, producing a spectrum of 19 distinct neuropsychiatric syndromes as defined by the American College of Rheumatology (ACR). NPSLE affects approximately 30–56% of SLE patients, with prevalence estimates varying widely by definition and attribution model (PMID: 41608446; PMID: 41307246). The condition is the second leading cause of death in SLE and a major contributor to irreversible organ damage, underscoring its clinical severity and the urgent need for improved diagnostic and therapeutic strategies.

Two fundamental pathogenic subtypes drive NPSLE manifestations: (1) an inflammatory/autoantibody-mediated pathway characterized by Type I interferon overproduction, blood-brain barrier (BBB) disruption, and CNS entry of autoantibodies (anti-NMDAR, anti-ribosomal P, anti-Sm), cytokines, and immune cells leading to neuroinflammation, microglial/astrocyte activation, impaired neurogenesis, and tryptophan-kynurenine metabolic reprogramming; and (2) a vascular/thrombotic pathway mediated by antiphospholipid antibodies causing cerebrovascular events and endothelial dysfunction. Treatment follows a tiered immunosuppressive approach ranging from hydroxychloroquine for all SLE patients through glucocorticoids and cyclophosphamide for severe disease to rituximab for refractory cases (94% response rate) and the emerging anti-IFNAR1 agent anifrolumab. Novel insights from single-cell and spatial transcriptomics have revealed spatially distinct IFN patches in brain parenchyma, choroid plexus T cell infiltration with myelin-specific clones, and early microglial activation preceding BBB disruption—findings that are reshaping mechanistic understanding and opening new therapeutic avenues.

This report synthesizes evidence from 104+ primary publications, 16 confirmed research findings across 5 investigative iterations, and comprehensive ontology mapping across 7 systems (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) to provide a complete disease knowledge base entry for NPSLE.

1. Disease Information

Overview

Neuropsychiatric Systemic Lupus Erythematosus (NPSLE) is a subset of SLE characterized by neurological and psychiatric manifestations resulting from autoimmune-mediated injury to the central nervous system (CNS), peripheral nervous system (PNS), and autonomic nervous system. The 1999 ACR nomenclature defines 19 distinct neuropsychiatric syndromes, divided into 12 CNS syndromes (headache, seizure disorder, cerebrovascular disease, demyelinating syndrome, movement disorder, myelopathy, acute confusional state, anxiety disorder, cognitive dysfunction, mood disorder, psychosis, aseptic meningitis) and 7 PNS syndromes (Guillain-Barré syndrome, autonomic disorder, mononeuropathy, myasthenia gravis, cranial neuropathy, plexopathy, polyneuropathy).

Key Identifiers

System Identifier
MONDO MONDO:0007915 (Systemic lupus erythematosus)
ICD-10 M32.1 (SLE with organ or system involvement); G99.8* (Other specified disorders of nervous system in diseases classified elsewhere)
ICD-11 4A40.6 (Systemic lupus erythematosus with neuropsychiatric involvement)
MeSH D020945 (Lupus Vasculitis, Central Nervous System)
OMIM 152700 (Systemic Lupus Erythematosus)
Orphanet ORPHA:536 (Systemic lupus erythematosus)

Synonyms and Alternative Names

  • Neuropsychiatric lupus (NP-lupus)
  • Cerebral lupus / CNS lupus / Neurolupus
  • Lupus cerebritis
  • Central nervous system lupus
  • Neuropsychiatric SLE (NPSLE)

Information Sources

This characterization is derived from aggregated disease-level resources including systematic reviews, meta-analyses, prospective cohort studies (GLADEL, CSTAR, LUMINA, 1000 Faces of Lupus), and registry data, supplemented by individual patient case series and mechanistic studies in animal models.

2. Etiology

Disease Causal Factors

NPSLE is a multifactorial autoimmune disorder with no single causative factor. Its etiology involves the interplay of genetic susceptibility, environmental triggers, hormonal influences, and dysregulated immune responses that collectively lead to autoimmune attack on neural tissues.

Genetic Risk Factors

Multiple genetic polymorphisms have been associated with NPSLE susceptibility:

Gene/Locus Variant Association Reference
TNFAIP3 rs5029939 (CG genotype) Significantly associated with neuropsychiatric manifestations (p<0.05) PMID: 35382378
TNF-α -238 G/A (A allele) Associated with neuropsychiatric impairment (p=0.036) PMID: 41039983
IL17RA rs2895332 Associated with NPSLE susceptibility in pediatric lupus nephritis PMID: 39904110
IL23R rs10889677 Associated with NPSLE susceptibility in pediatric lupus nephritis PMID: 39904110
FCGR3A rs396991 Associated with NPSLE susceptibility in pediatric lupus nephritis PMID: 39904110
HLA region Multiple alleles MHC region is the most significant genetic risk factor for autoimmunity onset PMID: 42123548

A Korean GWAS identified novel NPSLE-specific loci with functional roles in brain regions, suggesting genetic variants may specifically predispose to neuropsychiatric over other SLE manifestations (PMID: 41062154). Importantly, schizophrenia polygenic risk scores showed no association with NPSLE (OR 1.04, 95% CI 0.87–1.26), indicating distinct genetic architectures between lupus psychosis and primary psychiatric illness (PMID: 34599046).

The genetic architecture of NPSLE is polygenic/multifactorial, with incomplete penetrance and variable expressivity. No single Mendelian gene causes NPSLE, though rare monogenic lupus (e.g., complement deficiencies C1q, C2, C4) can present with neuropsychiatric features.

Environmental Risk Factors

  • UV radiation: Established environmental trigger that interacts with genetic susceptibility to initiate SLE; UV exposure can precipitate flares including neuropsychiatric events (PMID: 27306639)
  • Epstein-Barr virus (EBV) infection: EBV-positive childhood SLE patients had significantly higher frequencies of neurological symptoms (66.2% vs 45.2%) compared to EBV-negative patients (PMID: 41668759)
  • Vitamin D deficiency: Associated with neuropsychiatric manifestations; preclinical models demonstrate neuroprotective and barrier-stabilizing actions of vitamin D analogs (PMID: 41157255)
  • Adverse childhood experiences (ACEs): Associated with NPSLE (adjusted OR=3.40, 95% CI 1.55–7.78, p=0.003) — a novel finding with important clinical implications (PMID: 42009372)
  • Hormonal factors: Female sex hormones (estrogen) contribute to SLE susceptibility; SLE has a ~9:1 female:male ratio
  • Smoking: Associated with increased SLE disease activity and damage (PMID: 30657064)
  • Toluene exposure: Neurological symptoms may mimic NPSLE (PMID: 23956915)
  • Seasonal patterns: Vitamin D nadir in late winter/early spring correlates with increased SLE activity (PMID: 28624334)

Protective Factors

  • Hydroxychloroquine (HCQ): Protective against seizures (HR=0.35, 95% CI 0.15–0.80, p=0.0131) (PMID: 17875548); antimalarials reduce overall damage accrual (PMID: 41739063)
  • Vitamin D supplementation: Safely corrects deficiency with signals of benefit for selected outcomes (PMID: 41157255)

Gene-Environment Interactions

Genetic interactions with environmental factors, particularly UV light exposure, EBV infection, and hormonal factors, initiate disease, resulting in immune dysregulation at the level of cytokines, T cells, B cells, and macrophages (PMID: 27306639). Epigenetic modifications (DNA methylation, histone modifications) serve as a critical interface: hypomethylation of the HTR1A promoter region with overexpression of HTR1A mRNA in SLE peripheral blood lymphocytes directly links immune dysregulation to serotonergic signaling (PMID: 21382916). KDM6 lysine demethylases fine-tune transcription of pro- and anti-inflammatory genes, influencing Th17 cell expansion and autoimmunity (PMID: 40516332).

3. Phenotypes

Neuropsychiatric Syndrome Prevalence

The 19 ACR-defined NPSLE syndromes and their approximate frequencies are presented below:

Adults (based on PMID: 11971089; PMID: 11327248):

Syndrome Frequency (%) HPO Term
Headache 4–57% HP:0002315 (Headache)
Cognitive dysfunction 21–80% HP:0100543 (Cognitive impairment)
Mood disorder 6–47% HP:0000716 (Depression)
Anxiety disorder 7–24% HP:0000739 (Anxiety)
Seizure disorder 9–28% HP:0001250 (Seizures)
Cerebrovascular disease 2–19% HP:0002637 (Cerebral ischemia)
Psychosis 5–23% HP:0000709 (Psychosis)
Acute confusional state 1–16% HP:0001289 (Confusion)
Polyneuropathy 1–22% HP:0001271 (Polyneuropathy)
Movement disorder 1–9% HP:0100022 (Movement abnormality)
Myelopathy 4–8% HP:0002196 (Myelopathy)
Cranial neuropathy 1–3% HP:0001291 (Cranial nerve palsy)
Demyelinating syndrome 1–3% HP:0007305 (CNS demyelination)
Aseptic meningitis 1–5% HP:0002581 (Recurrent meningitis)
Mononeuropathy 1–8% HP:0007002 (Mononeuropathy)
Guillain-Barré syndrome 0.5–2.5% HP:0007166 (Paresthesia/tingling)

Childhood-onset SLE (meta-analysis, n=1463; PMID: 31022053): headache 52.2%, seizure disorders 48.6%, cognitive dysfunction 32.9%, mood disorder 28.3%, psychosis 22.7%, cerebrovascular disease 19.5%, acute confusional state 15.7%, movement disorder 9.4%, anxiety disorder 7.2%.

Phenotype Characteristics

  • Age of onset: Most commonly young adult (20–40 years); pediatric onset (<18 years) in ~15–20% of SLE cases, with higher NP damage (21% in early-onset <6 years) (PMID: 28134038)
  • Severity: Variable — ranges from mild cognitive dysfunction and headache to life-threatening seizures, coma, and stroke
  • Progression: Episodic and relapsing-remitting in most patients; some develop progressive cognitive decline
  • Temporal pattern: NP events affect 50–60% at SLE onset or within the first year; however, the majority of NP symptoms did NOT first present around the time of SLE onset (PMID: 39429812)

Quality of Life Impact

Patients consider fatigue, anxiety, depression, pain, psychosis, and cognitive dysfunction to be among their most debilitating symptoms which most diminish their quality of life (PMID: 40818249). Standardized neuropsychological testing reveals: 21% normal, 43% mild impairment, 30% moderate impairment, 6% severe impairment (PMID: 11971089). Recognition and attribution of these frequently non-acute symptoms is difficult, resulting in underassessment and underdiagnosis.

4. Genetic/Molecular Information

Susceptibility Genes and Variants

NPSLE is a polygenic complex trait without classic Mendelian inheritance. Key susceptibility genes include:

  • TNFAIP3 (A20): rs5029939 CG genotype — involved in NF-κB signaling regulation (PMID: 35382378)
  • TNF-α: Promoter polymorphism -238 G/A — modulates TNF-α expression (PMID: 41039983)
  • IL17RA / IL23R: Th17 pathway genes — rs2895332 and rs10889677 (PMID: 39904110)
  • FCGR3A: Fc-gamma receptor — rs396991 — modulates immune complex clearance (PMID: 39904110)
  • IRF5: Interferon regulatory factor 5 — associated with SLE susceptibility and organ damage (PMID: 41039983)
  • HLA class II alleles: MHC region variants — strongest genetic risk factor for SLE overall (PMID: 42123548)

Epigenetic Information

  • DNA hypomethylation: Global DNA hypomethylation in SLE T cells; HTR1A promoter hypomethylation leads to serotonin receptor overexpression (PMID: 21382916)
  • Histone modifications: KDM6A/KDM6B demethylases regulate H3K27me2/3, influencing Th17 expansion and autoimmunity (PMID: 40516332)
  • Glycosylation epigenetics: Epigenetic regulation of glycogenes affects immune function in SLE (PMID: 34495535)
  • No chromosomal abnormalities specific to NPSLE have been identified

5. Environmental Information

Environmental Factors

Factor Evidence Reference
UV radiation Triggers SLE flares including NP events PMID: 27306639
Toluene/solvents Can cause NP symptoms mimicking NPSLE PMID: 23956915
Adverse childhood experiences OR=3.40 for NPSLE PMID: 42009372

Infectious Agents

  • Epstein-Barr virus (EBV) (NCBI Taxon: 10376): Established trigger; molecular mimicry with self-antigens; EBV-positive childhood SLE patients had 66.2% neurological symptoms vs 45.2% EBV-negative (PMID: 41668759)
  • Varicella-Zoster virus (HZ): Higher HZ incidence in SLE with NP manifestations; psychosis and seizures associated with shorter time to HZ onset (PMID: 41871917)
  • Opportunistic infections (Listeria, fungi): CNS infections can mimic NPSLE in immunosuppressed patients (PMID: 41399085)

6. Mechanism / Pathophysiology

Central Pathogenic Axis: Type I IFN and BBB Disruption

The pathogenesis of NPSLE is an integrated neuroimmune process with two major mechanistic subtypes:

PATHOGENIC CASCADE — DIFFUSE NPSLE (Inflammatory)

Self-nucleic acids → TLR7/9 activation → pDC activation
                              ↓
              Type I IFN overproduction (IFN-α/β)
                              ↓
         Blood-Brain Barrier disruption ←── Anti-Sm antibodies
                              ↓
    ┌─────────────────────────┼─────────────────────────┐
    ↓                         ↓                         ↓
  Autoantibodies enter CNS    Cytokines enter CNS    Immune cells enter CNS
  (anti-NMDAR, anti-ribo P)   (IL-6, IFN-α, TNF-α)  (neutrophils/NETs, T cells)
    ↓                         ↓                         ↓
    └─────────────────────────┼─────────────────────────┘
                              ↓
              Microglial activation (M1 phenotype)
              Astrocyte reactivity (A1 phenotype)
                              ↓
    ┌─────────────────────────┼─────────────────────────┐
    ↓                         ↓                         ↓
   Synaptic loss/           Tryptophan → Kynurenine      Impaired hippocampal
   excitotoxicity           metabolic shift (IDO-1↑)      neurogenesis
   (NMDAR dysfunction)      (QA/KA ratio ↑,              (via IL-6, IL-18)
                     serotonin ↓)
    ↓                         ↓                         ↓
    └─────────────────────────┼─────────────────────────┘
                              ↓
    Cognitive dysfunction, depression, psychosis, seizures


PATHOGENIC CASCADE — FOCAL NPSLE (Vascular)

Antiphospholipid antibodies (aPL) → Endothelial activation
                              ↓
    ┌─────────────────────────┼─────────────────────────┐
    ↓                         ↓                         ↓
   Macro/microvascular      Complement activation      Immune complex
   thrombosis               (C3, C5a)                  deposition
    ↓                         ↓                         ↓
    └─────────────────────────┼─────────────────────────┘
                              ↓
              Cerebrovascular events
              (stroke, TIA, venous thrombosis)

Key Mechanistic Findings

1. Type I IFN as Central Driver: "Aberrant activation of innate immunity by self-nucleic acids and consequent overproduction of Type I interferons (IFN-I) constitute a central pathogenic axis in NPSLE" (PMID: 41989680). The BBB breach "permits peripheral autoimmune mediators—including pathogenic autoantibodies (e.g., anti-NMDAR, anti-ribosomal P), pro-inflammatory cytokines (e.g., Type I IFN, IL-6), and innate immune cells such as neutrophils forming Neutrophil Extracellular Traps (NETs)—to enter the central nervous system" (PMID: 41608446).

2. Early Microglial Activation Precedes BBB Disruption: A critical finding from NZB/W-F1 mice demonstrates that "at the prenephritic stage, BBB is intact yet mice exhibit hippocampus-related behavioural deficits recapitulating the human diffuse neuropsychiatric disease. This phenotype is accounted by disrupted hippocampal neurogenesis with hiNSCs exhibiting increased proliferation combined with decreased differentiation and increased apoptosis in combination with microglia activation" (PMID: 36898766). This challenges the traditional paradigm that BBB disruption is required for NPSLE onset.

3. Tryptophan-Kynurenine Metabolic Reprogramming: IFNγ drives diversion of tryptophan metabolism away from serotonin toward the kynurenine pathway, with "increased quinolinic acid/kynurenic acid (QA/KA) ratio and upregulation of indoleamine 2,3-dioxygenase-1" (PMID: 41869319). This provides a molecular explanation for depression and mood disorders in NPSLE.

4. Spatial IFN Signatures: Single-nucleus sequencing and spatial transcriptomics revealed that "interferon-stimulated genes (ISGs) were among the most highly upregulated genes" and "the type 1 interferon signature is enriched as spatially distinct patches within the brain parenchyma" (PMID: 37369340).

5. Choroid Plexus T Cell Infiltration: scRNA-seq identified clonal CD8+ T cells in the choroid plexus with a CDR3 sequence matching "a published T-cell receptor sequence with specificity for myelin basic protein. Systemic blockade of VLA-4, the cognate ligand of VCAM, resulted in significant resolution of the ChP immune cell infiltration and attenuation of the depressive phenotype" (PMID: 38531610).

6. Endothelial Dysfunction: "Cardiovascular disease (CVD) and neuropsychiatric manifestations are common in patients with SLE, often sharing a vascular origin with endothelial dysfunction central to their development" (PMID: 41795008). Focal neurologic symptoms result from "vascular injury induced by circulating immune complex, occlusive vasculopathy as a result of endothelial cell activation induced by cytokines and complement activation, or macro- and microvascular thrombosis induced by antiphospholipid antibodies" (PMID: 12491066).

Autoantibody-Specific Mechanisms

Autoantibody Target NPSLE Manifestation Mechanism Reference
Anti-NMDAR (anti-NR2) NMDA receptor Cognitive dysfunction, mood disorders Excitotoxic neuronal injury PMID: 29846157
Anti-ribosomal P Ribosomal P proteins Psychosis, depression Neuronal apoptosis PMID: 26524895
Anti-Sm Smith antigen BBB disruption (ACS) BBB permeability increase (p=0.0040) PMID: 29846157
Anti-β2GPI β2-glycoprotein I Psychosis (F=6.092, p=0.015) Thrombotic/inflammatory PMID: 38997542
Anti-cardiolipin Cardiolipin Demyelinating syndrome (F=6.637, p=0.011) Thrombotic vasculopathy PMID: 38997542
Antiphospholipid (LAC, aCL) Phospholipids Cerebrovascular disease Macro/microthrombosis PMID: 11327248

Key Molecular Pathways (with GO terms)

  • Type I interferon signaling (GO:0060337)
  • NF-κB signaling (GO:0038061)
  • Tryptophan-kynurenine metabolism (GO:0019441 — tryptophan catabolic process to kynurenine)
  • Complement activation (GO:0006956)
  • Apoptotic process (GO:0006915)
  • Microglial cell activation (GO:0001774)
  • Neuroinflammatory response (GO:0150076)
  • Neurogenesis (GO:0022008)

Cell Types Involved (with CL terms)

  • Microglia (CL:0000129) — M1 polarization, synaptic pruning
  • Astrocytes (CL:0000127) — A1 neurotoxic phenotype
  • Neurons (CL:0000540) — Target of excitotoxicity
  • Plasmacytoid dendritic cells (CL:0000784) — IFN-α production
  • CD8+ T cells (CL:0000625) — Choroid plexus infiltration
  • Neutrophils (CL:0000775) — NETosis, BBB disruption
  • B cells / Plasma cells (CL:0000236 / CL:0000786) — Autoantibody production
  • Neural stem cells (CL:0000047) — Impaired neurogenesis
  • Endothelial cells (CL:0000115) — BBB component, activation/dysfunction

Molecular Profiling

Transcriptomics: ISGs among most highly upregulated genes in brain (hindbrain, hippocampus) of NPSLE mice; gene pathways for cellular interaction and neuronal development repressed among astrocytes, oligodendrocytes, and neurons (PMID: 37369340).

Metabolomics: Cortical tryptophan-to-kynurenine diversion; increased QA/KA ratio; serotonin depletion; IDO-1 upregulation (PMID: 41869319). CSF HVA, SDF-1α, and SCGF-1β reduced in SLE patients with depression (PMID: 36852847).

Proteomics/Biomarkers: Elevated CSF IL-6, PAI-1 in NPSLE; shedding of sVCAM-1, sICAM-1, sPECAM-1, S100B reflects BBB disruption (PMID: 35118639).

7. Anatomical Structures Affected

Organ Level

  • Primary: Brain (UBERON:0000955), spinal cord (UBERON:0002240)
  • Secondary: Kidney (lupus nephritis), skin, joints, heart, lungs, blood vessels
  • Body systems: Nervous system (central and peripheral), immune system, cardiovascular system

Tissue and Cell Level

  • Hippocampus (UBERON:0001954) — Neurogenesis disruption, cytokine overexpression, atrophy
  • Cerebral cortex (UBERON:0000956) — White matter lesions, demyelination
  • Choroid plexus (UBERON:0001886) — T cell infiltration, immune gateway
  • Corpus callosum (UBERON:0002336) — White matter loss associated with elevated NfL (PMID: 34800169)
  • Basal ganglia (UBERON:0002420) — Calcifications, movement disorders
  • Limbic system — Mood and behavioral disturbances
  • Blood-brain barrier (endothelial cells, astrocyte endfeet, pericytes) — Disruption as key pathogenic step
  • Peripheral nerves — Polyneuropathy, mononeuropathy

Subcellular Level

  • Mitochondria (GO:0005739) — Mitochondrial dysfunction
  • Synapse (GO:0045202) — Synaptic loss and dysfunction
  • Cell nucleus (GO:0005634) — Target of anti-nuclear antibodies
  • Endoplasmic reticulum (GO:0005783) — Protein misfolding stress
  • Extracellular space (GO:0005615) — Neutrophil extracellular traps (NETs)

Lateralization

Generally bilateral; cerebrovascular events may be unilateral. Asymmetric presentation possible in focal NPSLE.

8. Temporal Development

Onset

  • Typical age: Young adult (20–40 years), peak incidence during reproductive years
  • Childhood onset: 15–20% of SLE cases; early-onset (<6 years) has highest NP damage (21%) and mortality (15%) (PMID: 28134038)
  • Onset pattern: Variable — acute (seizures, psychosis, stroke), subacute (progressive cognitive decline), or insidious (mood changes, fatigue)
  • Prodromal features: NP symptoms may be prodromal to SLE; 61% of SLE patients with hallucinations reported increasingly disrupted dreaming sleep (nightmares) prior to hallucination onset (PMID: 39429812)

Progression

  • Disease course: Episodic/relapsing-remitting predominant; some patients develop progressive cognitive decline
  • Duration: Chronic lifelong (in the context of SLE)
  • Critical periods: 50–60% of NP events occur at SLE onset or within the first year; seizures tend to occur early; 48% of childhood SLE deaths occurred within first 2 years (PMID: 28134038)
  • Remission: Treatment-induced remission achievable in most cases; spontaneous remission uncommon for severe manifestations

9. Inheritance and Population

Epidemiology

Measure Estimate Source
SLE prevalence 20–150 per 100,000 (varies by population) Multiple registries
NPSLE prevalence among SLE 6.4–80% (definition-dependent) PMID: 22595642
NPSLE prevalence (ACR attribution) ~30–40% PMID: 41307246
Childhood SLE incidence (China) 3.97 per 100,000 person-years PMID: 39299747

Inheritance Pattern

  • Multifactorial/polygenic — no Mendelian pattern
  • Incomplete penetrance — genetic susceptibility loci confer risk but do not guarantee disease
  • Variable expressivity — identical genetic backgrounds can produce different NP manifestations
  • No genetic anticipation documented

Population Demographics

  • Sex ratio: ~9:1 female:male for SLE overall; neuropsychiatric manifestations more equal across sexes
  • Ethnic groups: Higher prevalence and severity in African Americans, Hispanic Americans, Asians; Aboriginal populations show nearly 2-fold increase in NPSLE frequency (PMID: 22595642)
  • Age distribution: Peak onset in 2nd–4th decades; childhood SLE shows peripubertal increase (girls: +1.64/100,000/year per year of age increase) (PMID: 39299747)

10. Diagnostics

Clinical Tests

Laboratory Tests: - Complete blood count (cytopenias) - Complement levels (C3, C4 — typically decreased) - Anti-dsDNA, ANA, anti-Sm, anti-ribosomal P, anti-NMDAR antibodies - Antiphospholipid antibodies (aCL, LAC, anti-β2GPI) - CSF analysis: IL-6, Qα2MG (BBB disruption marker), IgG index, oligoclonal bands - Plasma neurofilament light (NfL) — correlates with CSF NfL (r=0.72, p<0.001) and brain atrophy (PMID: 34800169)

Biomarkers:

Biomarker Specimen Significance Reference
CSF IL-6 CSF Elevated in NPSLE, especially ACS PMID: 29036223
Qα2MG CSF/serum BBB disruption marker PMID: 29036223
Intrathecal PAI-1 CSF Elevated in NPSLE (p<0.05), correlates with neuronal damage PMID: 19565516
Plasma NfL Plasma Neuronal damage marker, correlates with cognitive impairment PMID: 36494778
CSF HVA CSF Reduced in SLE depression (p=0.04) PMID: 36852847
sVCAM-1, sICAM-1, S100B Serum BBB damage profile markers PMID: 35118639

Imaging: - Brain MRI: T2/FLAIR hyperintensities in cerebral white matter; diffusion-weighted imaging for acute lesions (PMID: 41638970) - DTI (diffusion tensor imaging): Abnormal white matter microstructure even in non-NPSLE SLE (PMID: 32349105) - FDG-PET: Altered brain metabolism - DCE-MRI: Increased BBB permeability - Volumetric MRI: Brain atrophy, hippocampal volume loss

Electrophysiology: EEG for seizure evaluation; EMG/NCS for peripheral neuropathy

Neuropsychological Testing: ACR-SLE battery; MADRS for depression screening (PMID: 36852847)

Clinical Criteria

  • 1999 ACR nomenclature: 19 NP syndrome case definitions (standard)
  • 2019 EULAR/ACR classification criteria: SLE classification with NP attribution
  • Attribution models: SLICC A, SLICC B, ACR — prevalence varies significantly by model used (PMID: 22595642)
  • 2023 EULAR management recommendations: Updated guidance for NPSLE diagnosis and treatment (PMID: 37827694)

NPSLE Subtypes by Clustering

Unsupervised clustering of 152 NPSLE patients identified two subgroups: Cluster 1 (23.7%) with cerebrovascular injury as predominant manifestation and higher antiphospholipid antibody positivity, and Cluster 2 with CNS-inflammatory manifestations (PMID: 41969819).

Differential Diagnosis

  • Multiple sclerosis
  • Primary CNS vasculitis
  • CNS infections (bacterial, viral, fungal — especially in immunosuppressed patients)
  • Primary psychiatric disorders
  • Neuromyelitis optica spectrum disorders
  • Thrombotic thrombocytopenic purpura
  • Drug-induced neuropsychiatric effects (corticosteroid psychosis)
  • Posterior reversible encephalopathy syndrome (PRES)

Genetic Testing

Genetic testing is not routinely indicated for NPSLE diagnosis. GWAS and polygenic risk scoring remain research tools. Testing for complement deficiencies (C1q, C2, C4) may be considered in early-onset or severe SLE.

11. Outcome/Prognosis

Survival and Mortality

  • NPSLE is the 2nd leading cause of SLE mortality (14.8% of deaths) after infection (30.1%) in Chinese cohorts (PMID: 28030595)
  • Independent predictor of mortality: NP involvement HR 2.03 (≤1 year) and HR 1.91 (>1 year) (PMID: 28030595)
  • Overall SLE 5-year survival: 95.7% (CSTAR registry) (PMID: 36465068)
  • Childhood SLE mortality: 0.7% in-hospital mortality; NPSLE is an independent risk factor for ICU admission (HR 2.10) (PMID: 39299747)
  • Early-onset SLE (<6 years): Highest mortality rate (15%) and highest NP damage (21%) (PMID: 28134038)

Organ Damage

NP damage is among the top 3 organ damage domains in SLE: - CSTAR registry: 12.2% of total organ damage (PMID: 36465068) - GLADEL cohort: 10.8% of total organ damage (PMID: 41739063) - Most frequent NP damages: cognitive dysfunction, valvulopathies, angina pectoris (PMID: 27889859)

Prognostic Factors

  • Poor prognosis: Male sex, late disease onset, delayed diagnosis (>1 year), baseline organ damage, high SLEDAI, high cumulative glucocorticoid dose
  • Better prognosis: Early diagnosis, antimalarial use, early immunosuppression, low glucocorticoid doses
  • Prognostic biomarkers: Plasma NfL (neuronal damage), CSF IL-6 (neuroinflammation), anti-Sm (BBB disruption)

12. Treatment

Pharmacotherapy

First-line (all SLE patients): - Hydroxychloroquine (CHEBI:5801): 5 mg/kg/day — recommended for ALL SLE patients (PMID: 37827694); protective against seizures HR=0.35 (p=0.0131) (PMID: 17875548); reduces overall damage accrual (PMID: 41739063) - MAXO:0001001 (pharmaceutical treatment)

Acute severe NPSLE: - Methylprednisolone pulse (CHEBI:6888): 500–1000 mg IV daily x 3 days, followed by oral taper - MAXO:0000750 (glucocorticoid therapy) - Cyclophosphamide (CHEBI:4026): IV pulses for severe NPSLE (seizures, psychosis, myelopathy, acute confusional state) - MAXO:0000750 (immunosuppressive therapy) - Intravenous immunoglobulin (IVIG): Adjunctive for severe cases - MAXO:0000376 (immunoglobulin therapy) - Plasma exchange (PLEX): For refractory cases - MAXO:0000127 (plasmapheresis)

Refractory NPSLE: - Rituximab (anti-CD20): 94.1% (16/17) refractory NPSLE patients achieved significant clinical improvement; none relapsed during median 45-month follow-up (PMID: 42115580) - MAXO:0001298 (B cell depletion therapy)

Emerging therapies: - Anifrolumab (anti-IFNAR1): Successful rescue therapy in 7/8 inflammatory NPSLE cases; "Blocking the IFNAR1 with anifrolumab provides a direct rationale for treating this subset of NPSLE" (PMID: 41756273) - Belimumab (anti-BAFF/BLyS): Approved for moderate-severe SLE; potential for NPSLE - VLA-4 blockade: Preclinical evidence — resolved choroid plexus infiltration and attenuated depressive phenotype (PMID: 38531610) - Captopril/ACE inhibitors: Potential neuroprotective agents preserving BBB function (PMID: 41831216) - GSK-J4 (KDM6 inhibitor): Small-molecule epigenetic therapy showing promise in models of chronic inflammation (PMID: 40516332)

Antithrombotic therapy (for focal/vascular NPSLE): - Anticoagulation with warfarin or direct oral anticoagulants for antiphospholipid-associated events - Aspirin for secondary prevention - MAXO:0000003 (anticoagulation therapy)

Supportive/Rehabilitative: - Cognitive rehabilitation, physical therapy, occupational therapy - Antidepressants (SSRIs) for mood disorders - Antiepileptic drugs for seizure control - Neuropsychological monitoring - MAXO:0000015 (cognitive behavioral therapy)

Treatment Algorithm

NPSLE Treatment Decision Tree:

1. ALL SLE patients → Hydroxychloroquine 5 mg/kg/day

2. Mild NPSLE (headache, mild cognitive, mild mood)
   → Optimize HCQ + Low-dose glucocorticoids + Supportive care

3. Moderate NPSLE (seizures, moderate cognitive, polyneuropathy)
   → Glucocorticoids + Immunosuppressant (azathioprine/mycophenolate)
   → Consider anticonvulsants for seizures

4. Severe NPSLE (psychosis, ACS, myelopathy, stroke)
   → Methylprednisolone pulse + Cyclophosphamide IV
   → IVIG or PLEX as adjunct
   → Distinguish inflammatory vs thrombotic:
     - Inflammatory → Immunosuppression
     - Thrombotic → Anticoagulation

5. Refractory NPSLE
   → Rituximab (94% response rate)
   → Anifrolumab for inflammatory NPSLE (emerging)

13. Prevention

Primary Prevention

  • UV protection: Sunscreen, protective clothing for all SLE patients
  • Smoking cessation: Reduces disease activity and flare risk
  • Vitamin D optimization: Supplementation to maintain adequate levels (PMID: 41157255)
  • Hydroxychloroquine: Protective against NP damage development (PMID: 41739063)

Secondary Prevention

  • Regular neuropsychological screening: MADRS and cognitive testing for subclinical NP involvement (PMID: 36852847)
  • Monitoring for prodromal symptoms: Disrupted dreaming/nightmares may precede psychosis and flares (PMID: 39429812)
  • Serial NfL monitoring: Plasma NfL as non-invasive neuronal damage biomarker (PMID: 34800169)
  • Advanced neuroimaging: Subclinical brain abnormalities detectable even in non-NPSLE SLE patients (PMID: 32349105)

Tertiary Prevention

  • Minimize glucocorticoid exposure: Chronic high-dose glucocorticoids trigger chronic organ damage (PMID: 27889859)
  • Target GC dose ≤5 mg/day prednisone equivalent (PMID: 37827694)
  • Antimalarial adherence: Lower proportion accruing NP damage with antimalarials (40.6% vs 48.3%) (PMID: 41739063)
  • Infection prophylaxis: Herpes zoster vaccination recommended (HZ incidence elevated in NPSLE patients) (PMID: 41871917)
  • Cardiovascular risk management: Shared vascular pathology between CVD and NPSLE (PMID: 41795008)

14. Other Species / Natural Disease

Naturally Occurring Disease

  • Canine SLE (NCBI Taxon: 9615 — Canis lupus familiaris): Naturally occurring SLE reported in multiple dog breeds; primarily cutaneous manifestations (discoid LE, vesicular CLE, exfoliative CLE); neurological manifestations rare but documented (PMID: 29669547). Affected breeds include German Shepherd, Shetland Sheepdog, Collie, and others. ANA testing in dogs can be confounded by vectorborne infections (Bartonella, Ehrlichia, Leishmania) (PMID: 14765731).

Comparative Biology

  • Canine distemper virus causes demyelination and CNS inflammation with microglial/astrocyte activation analogous to NPSLE; MIF (macrophage migration inhibitory factor) is elevated in affected brain tissue (PMID: 31981823)
  • Chronic Trypanosoma brucei infection induces meningeal ectopic lymphoid aggregates with GC-like B cells producing autoantibodies against brain antigens including myelin basic protein — paralleling choroid plexus findings in NPSLE (PMID: 37983289)

15. Model Organisms

Key Mouse Models

Model Type Key Features NP Phenotype Limitations Reference
MRL/MpJ-Fas^lpr^ (MRL/lpr) Spontaneous lupus Gold standard; Fas mutation; anti-dsDNA, anti-NMDAR, anti-P antibodies Depression (5 weeks F, 18 weeks M), anxiety, cognitive deficits, microglial activation Accelerated by Fas deficiency (not typical of human SLE) PMID: 20800292; PMID: 25183233
NZB/W-F1 Spontaneous lupus F1 hybrid; lupus nephritis dominant Hippocampal neurogenesis disruption, microglial activation with INTACT BBB at prenephritic stage Less pronounced NP phenotype PMID: 36898766
CReCOM Spontaneous lupus Behavioral deficits BEFORE systemic autoimmunity Reduced brain volumes, decreased vascular integrity, NP-SLE microglia signature (DAM-like), increased synaptic uptake Relatively new model PMID: 32174913
BXSB Spontaneous lupus Y-linked autoimmune accelerator Spontaneous SLE with NP features; hippocampal cytokine overexpression Male-predominant disease PMID: 14975498
Atherosclerosis-prone lupus mice Induced Combined lupus/atherosclerosis Cognitive deficits; responsive to resveratrol via A2A/SIRT1/VEGF/CX3CL1 Artificial combination PMID: 36081818

Key Findings from Animal Models

The MRL/lpr model demonstrates that "females exhibited significant depression as early as 5 weeks (at which time elevated levels of autoantibodies were already present), as compared to MRL/lpr males, where depression was noted only at 18 weeks. Depression was significantly correlated with autoantibodies against nuclear antigens, NMDA receptor, and ribosomal P" (PMID: 20800292).

The CReCOM model provides evidence that "SLE-prone mice develop NP-SLE, including behavioral deficits prior to systemic autoimmunity, reduced brain volumes, decreased vascular integrity, and brain-infiltrating leukocytes. NP-SLE microglia exhibit numerical expansion, increased synaptic uptake, and a more metabolically active phenotype" (PMID: 32174913).

The NZB/W-F1 model reveals that early NP features can occur with intact BBB: "at the prenephritic stage, BBB is intact yet mice exhibit hippocampus-related behavioural deficits" mediated by IL-6 and IL-18-induced neural stem cell apoptosis and microglial activation (PMID: 36898766).

Key Findings Summary

F001: NPSLE Prevalence and Heterogeneity

NPSLE affects 30–56% of SLE patients with 19 distinct syndromes. Prevalence varies enormously by definition used: 6.4% (ACR classification alone) to 80% (comprehensive ACR case definitions) (PMID: 22595642). This heterogeneity is a fundamental challenge for research and clinical management.

F002: Type I IFN/BBB Pathogenic Axis

The central pathogenic cascade involves Type I IFN overproduction → BBB disruption → CNS entry of autoantibodies and immune cells → neuroinflammation (PMID: 41989680; PMID: 41608446). However, early microglial activation can occur BEFORE BBB disruption (PMID: 36898766), challenging traditional models.

F003: Autoantibody-Specific Mechanisms

Different autoantibodies mediate distinct manifestations: anti-Sm drives BBB disruption (p=0.0040); anti-β2GPI associates with psychosis (p=0.015); anti-cardiolipin with demyelination (p=0.011) (PMID: 29846157; PMID: 38997542).

F004: Genetic Susceptibility

Multiple polymorphisms (TNFAIP3, TNF-α, IL17RA, IL23R, FCGR3A) confer NPSLE risk, but schizophrenia PRS shows no association (OR 1.04), confirming distinct genetic architecture from primary psychosis.

F005: NPSLE Mortality Impact

NPSLE is the 2nd leading cause of SLE death (14.8%), with NP involvement being an independent mortality predictor (HR ~2.0) (PMID: 28030595).

F006: Tryptophan-Kynurenine Metabolic Shift

IFNγ drives tryptophan away from serotonin toward kynurenine, increasing the neurotoxic QA/KA ratio — providing molecular explanation for NPSLE depression (PMID: 41869319).

F009: Treatment Efficacy

Rituximab achieves 94% response in refractory NPSLE with no relapse over median 45 months (PMID: 42115580); HCQ protects against seizures (HR=0.35) (PMID: 17875548); anifrolumab shows promise for inflammatory NPSLE (PMID: 41756273).

F013: Single-Cell/Spatial Transcriptomics Breakthroughs

Spatially distinct IFN patches in brain parenchyma (PMID: 37369340) and choroid plexus T cell infiltration with myelin-specific clones responsive to VLA-4 blockade (PMID: 38531610) represent paradigm-shifting findings.

F014: Prodromal Symptoms

NP symptoms may be prodromal to SLE; disrupted dreaming precedes hallucinations in 61% of patients. The majority of NP symptoms did NOT first present around time of SLE onset, challenging prevailing clinical assumptions (PMID: 39429812).

Evidence Base

Landmark Reviews and Studies

Paper PMID Key Contribution
Pathogenesis and therapeutic strategies for NPSLE centered on innate immune activation 41989680 Establishes Type I IFN as central pathogenic axis
Advancements in understanding neuropsychiatric lupus with single-cell resolution 41608446 Comprehensive neuroimmune cascade; prevalence data
Recent advances in pathogenesis of NPSLE 41872002 Neuroimmune framework for barrier-associated mechanisms
EULAR 2023 management recommendations 37827694 Current treatment guidelines
Spatial enrichment of type 1 IFN in NPSLE brain 37369340 First spatial transcriptomic evidence in NPSLE
Characterisation of choroid plexus-infiltrating T cells 38531610 Myelin-specific T cells; VLA-4 therapeutic target
Microglia activation with intact BBB 36898766 Early NP features precede BBB disruption
IFNγ-associated immune-metabolic remodeling 41869319 Tryptophan-kynurenine shift mechanism
NP syndromes using standardized definitions 11971089 Prevalence of all 19 syndromes
Rituximab in refractory NPSLE 42115580 94% response rate
NP prodromes (INSPIRE study) 39429812 Prodromal symptoms; disrupted dreaming

Limitations and Knowledge Gaps

  1. Attribution challenge: No gold-standard biomarker distinguishes NPSLE from non-SLE neuropsychiatric disease. Current attribution models (ACR, SLICC) yield highly variable prevalence estimates (6.4–80%), hindering clinical research and epidemiological comparisons.

  2. Absence of randomized clinical trials: All current treatment strategies for NPSLE are derived from clinical experience and extrapolation from other SLE manifestations or non-SLE neuropsychiatric disease. No RCTs have been conducted specifically for NPSLE.

  3. Heterogeneity: The 19 distinct syndromes likely have different pathogenic mechanisms, making "NPSLE" a heterogeneous umbrella rather than a single entity. The clustering into inflammatory vs vascular subtypes is a step forward but likely oversimplified.

  4. Translational gaps: Most mechanistic insights come from mouse models (MRL/lpr, NZB/W-F1, CReCOM), which imperfectly recapitulate human disease. The Fas mutation in MRL/lpr is not representative of typical human SLE genetics.

  5. CSF accessibility: Key diagnostic biomarkers (IL-6, Qα2MG, PAI-1) require lumbar puncture, limiting routine clinical use. Plasma NfL is promising but not specific to NPSLE.

  6. Cognitive dysfunction underassessment: Formal neuropsychological testing is rarely performed in acute settings; subclinical cognitive impairment likely affects many more patients than currently recognized.

  7. Epigenetic mechanisms: The role of DNA methylation, histone modifications, and non-coding RNAs in NPSLE pathogenesis is still poorly characterized compared to other SLE manifestations.

  8. Long-term outcomes: Limited data on long-term cognitive trajectories and neurodegeneration in NPSLE survivors.

Proposed Follow-up Experiments/Actions

  1. Randomized controlled trial of anifrolumab in inflammatory NPSLE: Building on the promising case series data (PMID: 41756273), a properly powered RCT stratifying patients by inflammatory vs vascular subtype is urgently needed.

  2. Prospective validation of prodromal dreaming disturbance: The INSPIRE finding that disrupted dreaming precedes psychosis (PMID: 39429812) warrants prospective validation as a clinical early warning system.

  3. Multi-omic biomarker panel development: Integration of plasma NfL, serum autoantibody profiles, and cytokine panels into a composite biomarker for NPSLE attribution and subtyping, avoiding lumbar puncture.

  4. VLA-4 blockade clinical trial: Natalizumab (anti-VLA-4), already approved for MS, should be explored for inflammatory NPSLE based on preclinical evidence of choroid plexus T cell resolution (PMID: 38531610).

  5. Human spatial transcriptomics: The spatial IFN patches identified in mouse brain (PMID: 37369340) need validation in human post-mortem NPSLE tissue to confirm translational relevance.

  6. IDO-1 inhibitor trials: Given the tryptophan-kynurenine metabolic shift (PMID: 41869319), IDO-1 inhibitors or kynurenine pathway modulators could be explored as adjunctive therapy for NPSLE-associated depression.

  7. Adverse childhood experience screening: Given the strong ACE-NPSLE association (OR=3.40) (PMID: 42009372), ACE screening should be integrated into SLE clinical care, with targeted psychosocial support.

  8. Longitudinal neuroimaging cohort: Serial advanced MRI (DTI, DCE-MRI, volumetric) with paired plasma NfL and cognitive testing to define progression trajectories and treatment response markers.

Report generated from 5 investigative iterations, 16 confirmed findings, and 104+ reviewed publications. Last updated: 2026-05-16.